WO2006118289A1 - 抗うつ作用を有する化合物の同定方法 - Google Patents
抗うつ作用を有する化合物の同定方法 Download PDFInfo
- Publication number
- WO2006118289A1 WO2006118289A1 PCT/JP2006/309118 JP2006309118W WO2006118289A1 WO 2006118289 A1 WO2006118289 A1 WO 2006118289A1 JP 2006309118 W JP2006309118 W JP 2006309118W WO 2006118289 A1 WO2006118289 A1 WO 2006118289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- dna
- seq
- cck
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9466—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Definitions
- the present invention relates to a method for identifying a compound having an antidepressant action. More specifically, the group consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the Sequence Listing and a splicing variant of the protein is an antagonist that is an antagonist of any one protein selected.
- the present invention relates to a method for identifying a compound having a depressing action.
- the present invention also relates to DNA encoding the splicing variant or its complementary strand, a recombinant vector containing the DNA or its complementary strand, and a transformant into which the recombinant vector has been introduced.
- the present invention relates to a protein translated from DNA encoding the splicing variant and a method for producing the protein.
- the present invention also includes a DNA comprising the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, a splicing variant of the DNA, and a DNA comprising at least one DNA selected from the DNA and the splicing variant of the DNA.
- the present invention relates to a reagent kit containing at least one of a replacement vector, a transformant introduced with the recombinant vector, a protein encoded by the DNA, and an antibody that recognizes the protein.
- the present invention relates to a function of any one of the proteins selected from the group consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein, and Z Alternatively, the present invention relates to an agent for improving depression including a compound that inhibits expression.
- the present invention also provides a function of any one protein selected from the group consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein, and Z Alternatively, the present invention relates to a method for improving a depressed state by inhibiting expression.
- the present invention relates to a preventive and Z or therapeutic agent for depression comprising an effective amount of the above-mentioned agent for improving depression.
- the present invention also relates to a method for preventing and / or treating depression using the agent for improving depression or the method for improving depression.
- the present invention relates to a method for quantitatively or qualitatively measuring a splicing variant of DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing or a complementary strand thereof, or a protein encoded by the splicing variant. .
- the present invention also provides a sequence listing.
- Membrane protein receptors are proteins that have a domain that penetrates the lipid bilayer of biological membranes, exist in cell membranes, specifically recognize various physiologically active substances, transmit their actions, and express them. .
- a physiologically active substance that specifically binds to a membrane protein receptor is generally referred to as a ligand.
- the ligand include peptide hormones, neurotransmitters, growth factors and the like.
- a ligand binds to a membrane protein receptor, a cellular response is evoked through formation of a second messenger, changes in intracellular ion concentration, protein phosphate, and the like.
- a series of reactions in which the binding of ligands to membrane protein receptors results in the formation of second messengers in cells, changes in intracellular ion concentrations, and changes in protein phosphorylation, etc. This series of reaction processes is called an information transmission path.
- G-protein coupled receptor GPCR coupled receptor, hereinafter abbreviated as GPCR
- GPCR G-protein coupled receptor
- GPCR coupled receptor is a glycoprotein present in the cell membrane and has a structural feature that it has seven transmembrane domains. It is a type of seven-pass receptor and constitutes a superfamily with many members. More than 1000 types of GPCR genes have already been identified, and research on the three-dimensional structure of GPCRs, ligands for GPCRs, intracellular information transfer pathways through GPCRs, and their functions are underway.
- GPCRs are receptors for light, odor, and taste, as well as receptors for hormones and neurotransmitters, and act as major cellular sensors in living organisms, from yeast to humans.
- G protein is a protein that is coupled to GPCR and functions as a signal transduction factor.
- G proteins are roughly classified into several families based on the functions of various factors involved in signal transduction in the intracellular signal transduction pathway (hereinafter referred to as “effector one”) and the gene encoding the protein.
- effector one the gene encoding the protein.
- G proteins belonging to any family are «,
- GDP-binding G protein is an inactive form that has no effect on effectors.
- GTP-binding G protein is called active form, and rapidly dissociates into GTP-bound dimer (j8 ⁇ ) consisting of a subunit (a GTP) and j8 and ⁇ subunits.
- a GTP and ⁇ directly act on effectors (for example, calcium ion channels and potassium ion channels) to activate intracellular signal transduction pathways, resulting in numerous cellular responses.
- hBAI 2 human brain angiogenesis inhibitor 2
- class B Secretin like
- TSP-I domain a thrombosbondin type I domain
- ⁇ a homologue of BAI2
- TSP-I domain is a characteristic domain found in the region represented by the amino acid sequence from the 385th to 522nd amino acids of thrombospondin. It is involved in the extracellular matrix of thrombospondin and its It is known to be an important functional domain for the ability to inhibit angiogenesis! /
- Mouse BAI2 which is a gene related to hBAI2, is expressed in the brain tissue of cerebral ischemia model rats by BAI2 and vascular endothelial growth factor (VEGF). It has been reported that there is a negative correlation between the expression level and the factor), and it may be involved in angiogenesis as well as hBAIl. Specifically, after hypoxia, BAI2 expression decreased and VEGF expression increased thereafter. In addition, the existence of a splicing variant of mouse BAI2 has been reported (Non-patent Document 3).
- hBAIl and hBAI2 are expected to be GPCR families based on sequence information, there are no reports referring to their functions as GPCRs, including information on ligands.
- CCK cholecystokinin
- CCK is known to be sulfated at the 7th tyrosine residue from the C-terminal side.
- post-translational processing results in fragments of several lengths, such as CCK-4, CCK-8, CCK-12, CCK-33, and CCK-58, with different N-terminal cleavage sites. It has been confirmed that the bioactivity and abundance of these fragments are different.
- cerulein extracted from the skin strength of Rie El has been reported as a compound having a chemical structure similar to CCK and exhibiting the same biological activity!
- CCK is also widely distributed in brain tissue, eg, cerebral cortex, hippocampus, amygdala and hypothalamus, and is involved in anxiety, analgesia, sedation, feeding suppression, memory and learning
- DA Dopamine
- GABA ⁇ aminobutyric acid
- 5HT serotone; 5-hydroxytryptamine
- CCK-8 which exists in the brain, is a cholecystokinin octapeptide sulphated form of Cholecystokinin Peptide Sulfated (CCK-8S) in which the 7th tyrosine residue from the C-terminal side is sulfated. ulfated form).
- CCK is essential for retention of memory.
- CC K 8S it is difficult to bring memory back to consciousness and take action, and CCK-4 (CCK-33 C-terminal tetrapeptide) prevents memory recall. It's obvious.
- CCK A receptor and CCK B receptor have been reported as CCK receptors. These are all G protein-coupled receptors.
- the expression of CCKA receptor has been detected in tissues and cells derived from the gastrointestinal tract and leukocytes in blood.
- the CCKA receptor is involved in the regulation of digestion through the promotion of effectors such as phospholipase C and adenyl cyclase in the intracellular signal transduction pathway.
- the expression of CCK B receptor has been detected in tissues and cells derived from the brain and digestive tract, and leukocytes in blood.
- the CCK B receptor is also referred to as a gastrin receptor and is involved in the regulation of digestion and cell proliferation in the intracellular signal transduction pathway through the promotion of effectors such as phospholipase C and intracellular calcium ion influx.
- effectors such as phospholipase C and intracellular calcium ion influx.
- the relationship between CCK B receptors and anxiety has attracted attention.
- Non-Patent Document 1 Shiratsuchi, T. et al., "Cytogenetics and cell genetics", 1997, 79th, p. 103 108.
- Non-Patent Document 2 -Nishimori, H. et al., "Oncogene”, 1997, 15th, p. 2145-2150.
- Non-Patent Document 3 Kee, H. J. et al., “Journal of Cerebral Blood Flow and Metabolism”, 2002, Vol. 22, pages 1054-1067.
- Non-Patent Document 4 Kaur B. et al., “American Journal Of Pathology”, 2003, 162, p. 19-27.
- GPCR serves as an important sensor of cells in the living body, and is a major target molecule in developing therapeutic agents for various diseases. Many GPCRs have already been found The identification of new GPCRs can be expected to make a significant contribution in the field of drug development.
- the present inventors have made diligent efforts to solve the above problems, and have found a protein that functions as a functional membrane protein receptor having a seven-transmembrane domain, which is considered to be a GPCR, and a gene that codes the protein.
- the gene product was successfully obtained using the gene.
- animal cells expressing the gene it was demonstrated that the protein is expressed on the cell membrane, and that a cellular response via intracellular signal transduction occurs by ligand stimulation.
- the TSP-I domain which is known to interact with a protein involved in intracellular signal transduction in its C-terminal region and to be involved in an angiogenesis inhibitory function in its amino acid sequence, is added to the protein. Clarified that it has three.
- CCK-8S acts as a ligand for the functional membrane protein receptor.
- a splicing variant of the gene has been found. And the protein power encoded by the splicing variant, like the protein encoded by the gene, is expressed on the cell membrane when expressed in animal cells, and produces a cellular response via intracellular signal transduction by ligand stimulation. Proved that.
- the function of the protein encoded by the gene is inhibited by using an experimental system in which an animal cell expressing the gene is stimulated with a ligand to generate a cellular response. It was proved that a compound to be identified can be identified.
- the gene is strongly expressed in brain tissue, particularly cerebral cortex, hippocampus and amygdala.
- the present inventors also found that the gene and its splicing variant are involved in depression.
- the present invention has been completed based on these findings.
- the present invention is a method for identifying a compound having an antidepressant action that is an antagonist of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 of the sequence listing or a homologous protein thereof.
- a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the Sequence Listing or a homologue DNA thereof, a protein encoded by the DNA, and a group force comprising the DNA selected from at least one selected from It relates to the characteristic identification method.
- the present invention also provides a protein of any one selected from the group consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein.
- a method for identifying a compound having an antidepressant activity which is an antagonist of a DNA having a base sequence that has one of the DNA represented by the base sequence set forth in SEQ ID NO: 1 in the sequence listing and the DNA that is a splicing variant thereof.
- the present invention relates to an identification method characterized by using at least one selected from DNA represented, a protein encoded by the DNA, and a group force that is a cell force containing the DNA.
- the present invention further includes a group force consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein.
- a method for identifying a compound having an antidepressant action that is an antagonist of the protein of any one of the nucleotide sequences set forth in SEQ ID NOs: 1, 15, 17, 19, and 21 in the sequence listing, and is represented by any one of the nucleotide sequences
- the cell containing the DNA to be tested is contacted with the test compound, the function of the protein encoded by the DNA expressed on the cell membrane of the cell is measured, and compared with when the test compound is not contacted with the cell.
- the present invention relates to an identification method comprising determining that a test compound that decreases or eliminates the function of the protein is a compound having an antidepressant action.
- the function of the protein encoded by the DNA expressed on the cell membrane of the cell is a function of causing an increase in intracellular calcium concentration by adding a ligand of the protein. Regarding the method.
- the present invention also provides that the function of a protein encoded by DNA expressed on the cell membrane of a cell is a function of causing a change in membrane potential by adding a ligand of the protein. Related to the determination method.
- the present invention further includes the following groups:
- the present invention further relates to a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 in the sequence listing or a complementary strand thereof.
- the present invention also relates to a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 in the sequence listing or a complementary strand thereof.
- the present invention further includes a DNA containing the DNA represented by the base sequence set forth in SEQ ID NO: 15 in the sequence listing, the DNA represented by the base sequence set forth in SEQ ID NO: 17 in the sequence listing or a complementary strand thereof. It relates to a replacement vector.
- the present invention further relates to a transformant into which the above recombinant vector has been introduced.
- the present invention is also encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 in the sequence listing, the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 in the sequence listing, or a complementary strand thereof.
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 in the sequence listing the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 in the sequence listing, or a complementary strand thereof.
- proteins are also encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 in the sequence listing, the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 in the sequence listing, or a complementary strand thereof.
- the present invention further relates to a protein represented by the amino acid sequence set forth in SEQ ID NO: 16 in the sequence listing.
- the present invention further relates to a protein represented by the amino acid sequence set forth in SEQ ID NO: 18 in the sequence listing.
- the present invention also provides DNA containing the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 of the sequence listing, the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 of the sequence listing, or a complementary strand thereof. Culturing a transformant introduced with a recombinant vector, The present invention relates to a method for producing the protein.
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing, the splicing variant of the DNA, the DNA and the splicing variant force of the DNA are also selected.
- the present invention relates to a reagent kit containing at least any one of a recombinant vector comprising, a transformant introduced with the recombinant vector, a protein encoded by the DNA, and an antibody that recognizes the protein.
- the present invention further provides a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the DNA represented by the nucleotide sequences set forth in SEQ ID NO: 1, 15, and 17 in the sequence listing. Any one of the amino acid sequences represented by SEQ ID NOs: 2, 16, and 18 in the Sequence Listing. It is related with the said reagent kit which is protein represented.
- the present invention also provides a group force consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein.
- the present invention relates to a method for improving a depression state by inhibiting function and Z or expression.
- the present invention further relates to a method for preventing and / or treating depression using the method for improving depression.
- the present invention also provides at least one DNA selected from the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the DNA, and Z or the DNA.
- the present invention relates to a measurement method for use in diagnosis of depression, which comprises quantitatively or qualitatively analyzing a protein encoded by as a marker.
- the present invention is also encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and DNA of at least one selected from splicing variants of the DNA, and Z or the DNA.
- the present invention relates to a method for diagnosing depression, which comprises quantitatively or qualitatively analyzing protein as a marker.
- a protein that acts as a functional membrane protein receptor having a 7-transmembrane domain, which is considered to be a GPCR, and a DNA encoding the protein.
- This protein is expressed on the cell membrane when expressed in cells, and intracellular information is obtained by ligand stimulation. Activates transmission and triggers cellular responses.
- the present invention it is possible to elucidate and regulate information transmission pathways and cell functions involved in the present protein.
- the present invention also makes it possible to prevent diseases caused by abnormalities of the protein and Z or DNA, such as depression, and to perform Z or treatment.
- FIG. 1-A is a schematic diagram showing the functional domain of the protein represented by the amino acid sequence set forth in SEQ ID NO: 2 in comparison with the protein encoded by hBAI2. (Example 1)
- FIG. 1-B is a schematic diagram showing the structural features of the protein represented by the amino acid sequence set forth in SEQ ID NO: 2 in comparison with its splicing variants.
- ph01207 represents a protein represented by the amino acid sequence set forth in SEQ ID NO: 2.
- 7tmHR, hkO 1941 and variant 3 all represent a splicing variant of the protein represented by the amino acid sequence set forth in SEQ ID NO: 2. (Example 6)
- FIG. 1-C shows a comparison of the amino acid sequences of the protein represented by the amino acid sequence shown in SEQ ID NO: 2 and its splicing variant.
- the double underline indicates the thrombosbond type I domain (TSP—I domain), and the underline indicates the transmembrane domain.
- ph01207 represents a protein represented by the amino acid sequence set forth in SEQ ID NO: 2.
- 7tmHR, hk01941 and variant 3 each represent a splicing variant of the protein represented by the amino acid sequence set forth in SEQ ID NO: 2. (Example 6)
- FIG. 2 When cDNA clone ph01207 was expressed as FLAG-tag fusion protein and HA-tag fusion protein in animal cell line CHO-K1 cells, these proteins were expressed on the cell membrane. (Left panel and right panel respectively). Proteins on the cell membrane were analyzed by fluorocytometry using anti-FLAG-tag antibody, anti-HA-tag antibody and FITC-labeled secondary antibody (FITC-anti-mouse IgG antibody). In the figure, the region shown in black represents cells expressing each tag fusion protein, and the region shown in white represents control cells that did not express the protein. (Example 2)
- FIG. 4-A InM CCK-8S (SEQ ID NO: 14) in the CHO-K1 cell line (HA-ph01207 # 10-6), which stably expresses cDNA clone ph01207 as an HA-tag fusion protein. ) Shows that the intracellular Ca 2+ concentration was increased. On the other hand, when the cDNA was transferred, the increase in intracellular Ca 2+ concentration by CCK-8S (SEQ ID NO: 14) was not observed in the CHO-K1 cell line! I got it.
- the horizontal axis shows the time (seconds) from the start of measurement of intracellular Ca 2+ concentration (Time (sec)).
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration. (Example 5)
- FIG. 8 shows that no increase in intracellular Ca 2+ concentration due to (8 nonsulfated form) was observed.
- CCK-8NS is a CCK peptide expressed by the same amino acid sequence as CCK-8S, but is a peptide in which the seventh tyrosine residue from the C-terminus is not sulfated. No increase in intracellular Ca 2+ concentration due to CCK-8NS was observed even in the CHO-K1 cell line in which cDNA clone ph01207 was not transfected.
- the horizontal axis shows the time (sec) of the force after the measurement of intracellular Ca 2+ concentration was started.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye that reflects the Ca 2+ concentration.
- FIG. 4-C In a CHO-K1 cell line (HA-ph01207 # 10-6) that stably expresses cDNA clone ph01207 as an HA-tag fusion protein It is a figure which showed that the raise of Ca ⁇ 2+ > density
- the horizontal axis shows the time (sec) after the start of measurement of intracellular Ca 2+ concentration.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration. (Example 5)
- FIG. 4-D In the CHO-K1 cell line (HA-ph01207 # 10-6), which stably expresses the cDNA clone ph01207 as an HA-tag fusion protein, It is a figure which shows that Ca ⁇ 2+ > density
- the horizontal axis shows the time (seconds) from the start of measurement of intracellular Ca 2+ concentration (Time (sec)).
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration. (Example 5)
- FIG. 4-E CHO-K1 cell line (HA-ph01207 # 10-6), which stably expresses cDNA clone ph01207 as an HA-tag fusion protein, or transfection of the cDNA
- the horizontal axis indicates the time (seconds) of the force (Time (sec)) from the start of measurement of intracellular Ca 2+ concentration.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 5-A is a graph showing a typical result of increase in intracellular Ca 2+ concentration by InM CCK 8S (SEQ ID NO: 14) in a 7tmHR stable expression strain.
- 7tmHRZCHO # 6 means one clone of a 7tmHR stable expression strain
- CHO-K1 means a host cell.
- the horizontal axis shows the time (sec) of the force after the measurement of intracellular Ca 2+ concentration.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 5-B is a graph showing that intracellular Ca 2+ concentration was increased by 20 / z M of calcium ionophore A23187 in a 7tmHR stable expression strain. Even in host cells not transfected with the 7tmHR expression vector, an increase in intracellular Ca 2+ concentration due to A23187 was observed.
- 7tmHRZCHO # 6 means one clone of a 7tmHR stable expression strain
- CHO-K1 means a host cell.
- the horizontal axis shows the time (sec) after starting the measurement of intracellular Ca 2+ concentration.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 6A is a graph showing a typical result in which intracellular Ca 2+ concentration was increased by InM CCK-8S (SEQ ID NO: 14) in the hk01941 stably expressing strain.
- InM CCK-8S SEQ ID NO: 14
- hk0194lZCHO # 13 means one clone of hkOl 941 stable expression strain
- CHO-K1 means a host cell.
- Horizontal axis is intracellular The measurement of Ca 2+ concentration is started and the time (seconds) of force (Time (sec)) is shown. The vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 6-B shows that intracellular Ca 2+ concentration was increased by 20 / z M calcium ionophore A23187 in hk01941 stably expressing strain. Even in host cells not transfected with the hk01941 expression vector, an increase in intracellular Ca 2+ concentration due to A23187 was observed.
- hk0194lZCHO # 13 means one clone of a stable expression strain of hk01941
- CHO-K1 means a host cell.
- the horizontal axis shows the time (seconds) from the start of intracellular Ca 2+ concentration measurement.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent color reflecting the Ca 2+ concentration.
- FIG. 7-A This figure shows a representative result in which intracellular Ca 2+ concentration was increased by CCK-8S of InM (SEQ ID NO: 14) in a variant3 stable expression strain.
- CCK-8S of InM SEQ ID NO: 14
- variant3ZCHO # 14-18 means one clone of a stable expression strain of varia nt3, and CHO-K1 means a host cell.
- the horizontal axis shows the time (sec) of the force after the measurement of intracellular Ca 2+ concentration was started.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 7-B shows that intracellular Ca 2+ concentration was increased by 20 / z M calcium ionophore A23187 in variant3 stably expressing strain. Even in host cells not transfected with the variant3 expression vector, an increase in intracellular Ca 2+ concentration due to A23187 was observed.
- variant3ZCHO # 14-18 means one clone of & 1 ⁇ 1 ⁇ 3 stable expression strain, and CHO-K1 means host cell.
- the horizontal axis shows the time (seconds) from the start of intracellular Ca 2+ concentration measurement.
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent color reflecting the Ca 2+ concentration.
- FIG. 8-A Data showing that the phO 1207 gene is strongly expressed in human amygdala protoplast astrocytes by tissue immunostaining using anti-human BAI2 polyclonal antibody. It is. (Example 10)
- FIG. 8-B Data showing that the phO 1207 gene is strongly expressed in human amygdala -euron and glia by tissue immunostaining using anti-human BAI2 polyclonal antibody. It is a figure. (Example 10)
- FIG. 8-C is a diagram showing data analyzed by tissue immunostaining using an anti-human BAI2 polyclonal antibody that the ph01207 gene is strongly expressed in -euron in the CA2 region of the hippocampus. (Example 10)
- FIG. 8-D is a diagram showing data analyzed by tissue immunostaining using an anti-human BAI2 polyclonal antibody that the ph01207 gene is strongly expressed in -euron in the CA1 region of the hippocampus. (Example 10)
- FIG. 9-A The hippocampus of F1 heterozygous mouse produced using ES cells into which a targeting vector targeting the mouse BAI2 gene was introduced.
- the LacZ-Neo gene contained in the targeting vector was It is a figure which shows the result detected by LacZ expression analysis that it is expressing strongly. This result indicates that the LacZ-Neo fragment was inserted into the target site of the mouse BAI2 gene, that is, that the gene was destroyed, and that the mouse BAI2 gene was expressed in the hippocampus. (Example 11)
- FIG. 9-B The amygdala of an F1 heterozygous mutant mouse produced using ES cells into which a targeting vector targeting the mouse BAI2 gene has been introduced.
- the LacZ-Neo gene contained in the targeting vector It is a figure which shows the result detected by LacZ expression analysis that it is expressing strongly. This result indicates that the LacZ-Neo fragment was inserted into the target site of the mouse BAI2 gene, that is, that the gene was destroyed, and that the mouse BAI2 gene was expressed in the amygdala.
- FIG. 10 is a diagram showing immobility times of tail suspension tests using BAI2 knockout mice and wild-type mice.
- + Z + means a wild type mouse
- Z means a BAI2 knockout mouse.
- the tail suspension test was performed using 16 wild-type mice and 10 BAI2 knockout mice. The results are shown as the mean value (seconds) of the immobility time of each mouse in terms of standard error.
- an asterisk indicates that a significant difference (P 0.05) was observed in the statistical treatment using the t test.
- FIG. Ll-A In CHO-K1 cell line stably expressing cDNA clone ph01207, the increase of intracellular Ca 2+ concentration by CCK 8S of ⁇ was added with gZmL of compound A (compound A). It is a figure which shows having been inhibited by cocoon. Buff as control The buffer was added in place of Compound A. Compound A or buffer was added 15 seconds after the start of measurement, and CCK-8S was added 35 seconds after addition of compound A or buffer. The abscissa indicates the time (seconds) from the start of measurement of intracellular Ca 2+ concentration (Time (sec)). The vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration. (Example 12)
- FIG. 11-B In CHO-K1 cell line stably expressing cDNA clone ph01207, the increase of intracellular Ca 2+ concentration by CCK 8S of ⁇ was added with Compound B (compound B) of gZmL. It is a figure which shows having been inhibited by cocoon.
- a buffer was added instead of Compound B.
- Compound B or buffer was added 15 seconds after the start of measurement, and CCK-8S was added 35 seconds after addition of compound B or buffer.
- the abscissa indicates the time (seconds) from the start of measurement of intracellular Ca 2+ concentration (Time (sec)).
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- FIG. 11-C In CHO-K1 cell line stably expressing cDNA clone ph01207, the increase of intracellular Ca 2+ concentration by CCK 8S of ⁇ was added with Compound C (compound C) of gZmL. It is a figure which shows having been inhibited by the cocoon.
- a buffer was added instead of Compound C.
- Compound C or buffer was added 15 seconds after the start of measurement, and CCK-8S was added 35 seconds after addition of compound C or buffer.
- the abscissa indicates the time (seconds) from the start of measurement of intracellular Ca 2+ concentration (Time (sec)).
- the vertical axis shows the fluorescence intensity (RFU) of the fluorescent dye reflecting the Ca 2+ concentration.
- proteins may be used as a generic term.
- proteins, polypeptides or oligopeptides have a minimum size of 2 amino acids.
- amino acids they may be represented by one or three letters.
- the present invention relates to a protein that functions as a functional membrane protein receptor having a seven-transmembrane domain, and a DNA encoding the protein. More specifically, the present invention relates to a protein that functions as a G protein co-receptor and DNA encoding the protein.
- Membrane protein receptor is a protein having a domain that penetrates the lipid bilayer of biological membranes. It means a protein that is present in the cell membrane, specifically recognizes various physiologically active substances, transmits its action, and is expressed. Here, the protein includes glycoprotein. “Functional membrane protein receptor” means a membrane protein receptor having a function of inducing a cellular response through intracellular signal transduction by the action of a ligand. Membrane protein receptors have an extracellular domain that interacts with a ligand, a domain that penetrates the lipid bilayer of a biological membrane, and an intracellular domain that mediates intracellular signal transduction.
- G protein-coupled receptor means a membrane protein receptor that, when stimulated by a ligand, binds to a G protein present in a cell and activates the G protein.
- G protein is a protein that is coupled to GPCR. It is a protein that induces a number of cellular responses as an intracellular signal transduction factor by transferring to the GTP-binding G protein by the GDPZGTP exchange reaction. means.
- Activating G protein means inducing and / or promoting the transition from GDP-bound G protein to GTP-bound G protein by inducing and / or promoting GDP / GTP exchange reaction. The result is that the G protein is coupled to induce and Z or promote numerous cellular responses involving GPCRs.
- Ligand means a physiologically active substance that specifically interacts with a membrane protein receptor.
- Interaction means, for example, that two or the same or different protein forces act specifically, and as a result, one or both functions change, for example, increase or decrease. means.
- To act specifically means to act more selectively than a protein other than the protein involved in the action.
- the interaction includes, for example, the binding of two different proteins or the activity of the other protein by one protein.
- Intracellular signal transduction is a series of reactions in which the action of a ligand on a receptor causes formation of a second messenger, changes in intracellular ion concentration, changes in protein phosphate, etc.
- intracellular signal transduction pathway means the series of reaction processes.
- DNA used in the present invention more specifically has the base sequence set forth in SEQ ID NO: 1.
- DNA represented or its homologue DNA refers to a protein having sequence homology with the DNA of interest and a protein having structural features, such as similarity in biological function, etc. with the protein encoded by the DNA. DNA.
- the protein encoded by the DNA used in the present invention is preferably a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or a homologous protein thereof.
- the term “homolog protein” refers to a protein having sequence homology with a target protein and having similarity in structural characteristics, biological functions, and the like.
- the DNA and protein are preferably human-derived DNA and protein.
- the DNA and protein are derived from a mammal having the same function as that of the human-derived DNA and protein and having structural homology.
- DNA and protein such as mouse, horse, hidge, ushi, inu, monkey, cat, bear, rat or rabbit, etc.
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 is a DNA encoding a protein that functions as a functional membrane protein receptor having a 7-transmembrane domain. More specifically, the protein encoded by the DNA represented by the base sequence described in SEQ ID NO: 1 is preferably exemplified by the protein represented by the amino acid sequence described in SEQ ID NO: 2 in the Sequence Listing.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 has three TSP-I domains, one GPS (GPCR proteolytic site) domain, and one 7 It has a transmembrane domain (see Figure l-A and Figure l-B).
- the 7th transmembrane domain also called the GPCR family 2 domain, co-localizes with the GPS domain and is characteristic of G protein-coupled receptors.
- the TSP-I domain is a characteristic domain found in thrombosbondin, and is known to be a functional domain important for the involvement of thrombospondin in the extracellular matrix and its ability to inhibit angiogenesis.
- the DNA gene product represented by the nucleotide sequence set forth in SEQ ID NO: 1 actually showed a function as a membrane protein receptor. Specifically, in an animal cell in which the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 is expressed, the protein encoded by the DNA is expressed on the cell membrane, and ligand stimulation such as CCK 8S ( SEQ ID NO: 14) It was observed that a cellular response via intracellular signal transduction was generated by stimulation. [0085] In addition, the DNA gene product represented by the nucleotide sequence shown in SEQ ID NO: 1 interacts with MAGUK family-related proteins DLG2, DLG3 and DLG4, AIP1, MAGI3, etc. in its C-terminal region. Was observed.
- MAGUK family-related proteins have a PDZ domain that recognizes the most C-terminal amino acid sequence of the target protein in protein-protein interactions, and are localized in the cell membrane and interact with membrane proteins such as receptors and ion channels. By acting, it is thought to be involved in information transmission of these membrane protein forces and contribute to cell-cell adhesion and the like.
- the interaction between the hBAI2 gene gene product having sequence homology with the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 and the MAGUK family-related protein was also observed.
- BAP 1 (BAI 1 associated proteinl), one of the hBAIl force M AGUK family-related proteins, which are homologs of hBAI2, binds via a partial sequence (QTEV: SEQ ID NO: 3) of the terminal region of hBAIl.
- both the protein encoded by the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 and the protein encoded by the hBAI2 gene (SEQ ID NO: 21) having sequence homology with the gene are C-terminal. Since the amino acid sequence (QTEV) described in SEQ ID NO: 3 is conserved in the region, the inventors consider that this region interacts with a protein having a PDZ domain.
- the DNA homologue represented by the nucleotide sequence represented by SEQ ID NO: 1 preferably has sequence homology with the DNA represented by the nucleotide sequence represented by SEQ ID NO: 1, and CCK 8S ( It is a DNA encoding a protein that exhibits the same function as GPCR by the action of SEQ ID NO: 14).
- Preferred examples of the homolog DNA of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 include a splicing variant of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- a splicing variant of the protein encoded by the DNA represented by the sequence is preferably exemplified.
- Splicing variant is a gene expression in eukaryotes. Genomic force Two or more mature mRNAs generated by alternative splicing of mRNA precursors of a gene transcribed, complementary to the mature mRNA It means either target DNA or a protein whose mature mRNA force is also translated. Gene expression in eukaryotes means that mature mRNA is formed by splicing from the pre-transcribed mRNA precursors from the introns that exist between exons that are distributed on the genome and the exons. This is done. Sarako, a protein is produced by translation of the mature mRNA.
- Splicing refers to the process by which introns are excised from mRNA precursors at the splice site (boundary point between introns and exons) and mature mRNA is formed.
- so-called alternative splicing may occur in which the position and combination of splice sites change and two or more types of mature mRNA are generated.
- two or more proteins are often produced from one gene.
- the splicing variant of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 comprises two or more types of splicing generated by alternative splicing of an mRNA precursor transcribed from the genome of the gene consisting of the DNA. It can be mature mRNA or the complementary DNA of the mature mRNA.
- DNA represented by the base sequence set forth in SEQ ID NO: 15 is preferred. It can be illustrated.
- the DNA represented by the base sequence set forth in SEQ ID NO: 19 is encoded by the DNA represented by any one of the base sequences set forth in SEQ ID NOs: 1, 15, 17, 19, and 21. Encodes a protein having the longest amino acid sequence.
- the splicing variant of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 is not limited to the splicing variant exemplified above, has sequence homology with the DNA, and has structural characteristics of the DNA, Furthermore, as long as the DNA encodes a protein having the same biological function as the protein encoded by the DNA! [0095]
- the splicing variant of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 is generated by alternative splicing of the mRNA precursor of the gene encoding the protein transcribed from the genome. Two or more types of mature mRNA forces are translated proteins.
- any one of the base sequences described in SEQ ID NOs: 15, 17, 19, and 21 has a base sequence of 1
- the protein represented by the amino acid sequence described in SEQ ID NO: 20 is a protein having the longest amino acid sequence among the proteins represented by the amino acid sequences described in SEQ ID NOS: 2, 16, 18, 20, and 22. .
- the splicing variant of the protein encoded by the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 is not limited to the splicing variant exemplified above, and has a sequence homology with the protein, and the structure of the protein Any protein is included as long as the protein has specific characteristics and has the same biological function as the protein encoded by the DNA.
- the splicing variant of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 has sequence homology with the protein represented by the amino acid sequence set forth in SEQ ID NO: 2. Any protein is included as long as it has structural characteristics of the protein and has the same biological function as the protein.
- sequence homology is usually 50% or more, preferably at least 70%, of the entire base sequence or amino acid sequence. More preferably, it is 70% or more, further preferably 80% or more, still more preferably 90% or more, and even more preferably 95% or more.
- the DNA having sequence homology with the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 includes at least one DNA sequence represented by the nucleotide sequence represented by SEQ ID NO: 1, For example, 1 to 100, preferably 1 to 30, more preferably 1 to 20, more preferably 1 to 10, particularly preferably 1 to several nucleotides are deleted, substituted, added or inserted. It includes DNA represented by a base sequence in which a mutation exists.
- it is such a DNA that encodes a protein having the same function as the biological function of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- the degree of mutation and the position thereof have the same structural characteristics as the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1, and the DNA having the mutation is represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- it is not particularly limited.
- the DNA having a mutation may be a naturally occurring DNA or a DNA obtained by introducing a mutation based on a naturally occurring gene! / ⁇ .
- Means for introducing mutations are known per se. For example, site-directed mutagenesis, gene homologous recombination, primer extension, polymerase chain reaction (hereinafter abbreviated as PCR), etc. are used alone or in appropriate combination. Can be used. For example, the method described in the book (edited by Sambrook et al., “Molecular Cloning, Laboratory Trial 2nd Edition”, 1989, Cold Spring Nova Laboratory; Genetic engineering ", 1988, Maruzen Co., Ltd.), or by modifying those methods. Ulma's technology (Ulmer, KM)," Science ", 1983 Year 219, pp. 666-671) can also be used.
- the DNA used in the present invention includes the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 and the DNA that undergoes hybridization under stringent conditions to the splicing variant of the DNA.
- the conditions of the hybridization for example, the method described in the book (Sambrook et al., “Molecular Cloning, Laboratory My Second Edition”, 1989, Cold Spring Harbor Laboratory ) Etc. can be adopted.
- “under stringent conditions” means, for example, in a solution of 6 X SSC, 0.5% SDS and 50% honremamide42. This refers to the conditions of washing at 68 ° C in a solution of 0.1 X SSC, 0.5% S DS after warming at C.
- DNAs are the salts described in SEQ ID NO: 1.
- the DNA hybridizes to the DNA represented by the base sequence and the splicing variant of the DNA, it does not have to be a DNA having a complementary sequence.
- it is a DNA having the same function as the biological function of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- Examples of the protein having sequence homology with the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 include, for example, one or more in the amino acid sequence set forth in SEQ ID NO: 2, such as 1 to: LOO , Preferably 1-30, more preferably 1-20, even more preferably 1: LO, particularly preferably 1 to several amino acid deletions, substitutions, additions or insertions and V, And a protein having the same function as the biological function of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- the degree of amino acid mutation and the position thereof are not particularly limited as long as the protein has the same function as the protein represented by the amino acid sequence shown in SEQ ID NO: 2.
- a protein having a mutation may be a protein naturally occurring, for example, by mutation or post-translational modification, or may be obtained by introducing a mutation based on a gene derived from nature.
- Means for introducing mutations are known per se, and for example, site-specific mutation introduction method, gene homologous recombination method, primer extension method or PCR can be used alone or in appropriate combination.
- site-specific mutation introduction method for example, site-specific mutation introduction method, gene homologous recombination method, primer extension method or PCR can be used alone or in appropriate combination.
- the method described in the book edited by Sambrook et al., “Molecular Cloning, Laboratory Trial 2nd Edition”, 1989, Cold Spring Laboratory Laboratory; Muramatsu Masami, “Lab Manual” Genetic engineering ", 1988, Maruzen Co., Ltd.
- by modifying those methods are described in the book (edited by Sambrook et al., “Molecular Cloning, Laboratory Trial 2nd Edition”, 1989, Cold Spring Laboratory Laboratory; Muramatsu
- Structural features of DNA include the 7th transmembrane domain coding region and the TSP-I domain.
- An encoding area can be exemplified.
- the protein encoded by the DNA can be exemplified by seven transmembrane domains and TSP-I domains as structural features. Sequence homology in such domain regions is preferably at least 70%, more preferably 70% or more, even more preferably 80% or more, even more preferably 90% or more, and even more preferably 95%.
- the above DNA or protein is preferred. Further, these domains are more preferably domains that retain their functions, for example, the function of localizing a protein containing the domain in the membrane or the function of inhibiting angiogenesis.
- DNA includes that a region encoding the amino acid sequence (QTEV) described in SEQ ID NO: 3 is conserved in the terminal region.
- amino acid sequence (QT EV) described in SEQ ID NO: 3 is conserved in the C-terminal region.
- the function as a membrane protein receptor can be exemplified as the biological function of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 as the biological function.
- the “function as a membrane protein receptor” means a function that is expressed as a membrane protein when expressed in an animal cell, promotes intracellular signal transduction by the action of a ligand, and induces a cellular response.
- GPCR Genetic Repeat et alpha-1 ase ase a protein receptor
- “Functional equivalent to GPCR” refers to a function that binds to and activates G protein by the action of a ligand, promotes intracellular signal transduction, and induces a cellular response.
- cell responses include changes in cell membrane potential or changes in intracellular calcium concentration. Changes in cell membrane potential or intracellular calcium concentration can be measured by a method known per se. The change in cell membrane potential is caused by, for example, expressing a DNA represented by the nucleotide sequence of SEQ ID NO: 1 or a splicing noreant of the DNA in Xenopus laevis oocytes in the presence or absence of ligand stimulation. It can be detected by measuring the amount of current generated specifically for the membrane protein receptor and comparing the amount of current.
- Changes in intracellular calcium concentration include, for example, the incorporation of fluorescent dyes that can bind to calcium ions into the cell, causing fluorescence phenomenon by excitation light in the presence or absence of ligand stimulation, and comparing the amount of fluorescence. This can be detected.
- a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or a DNA strand examples include cells prepared with the expression of a pricing variant or samples prepared from biological tissue strength.
- the sample can be prepared by, for example, culturing cells or tissues by a method known per se and obtaining the culture supernatant by centrifugation or the like, or crushing or dissolving cells or tissues by a method known per se.
- the ligand can be used after being purified from these samples by a known protein purification method such as gel filtration chromatography.
- ligands include the culture supernatant of the HeLa cell line used in this example, but the ligand is not limited to this, and can act on the gene product of the present DNA expressed in cells to induce a cellular response. If so, you can use the gap.
- a preferred example of the ligand is CCK-8S (SEQ ID NO: 14).
- Proteins having the same function as the biological function of the protein encoded by the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 and having guanylate kinase activity and Z or cell adhesion function such as the MAGUK family Illustrate functions that interact with related proteins.
- MAGUK family-related proteins include DLG2, DLG3 and DLG4, AIP1, and MAGI3.
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 and the splicing variant of the DNA encode a protein that functions as a functional membrane protein receptor having a 7-transmembrane domain.
- the protein encoded by this DNA has several structural features, preferably two to four TSP-I domains, one GPS domain, and one seven-transmembrane domain ( Figure 1). —See A and Figure 1-B).
- the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 is a portion predicted to be a signal sequence
- Preferred examples of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 include the protein represented by the amino acid sequence set forth in SEQ ID NO: 2.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 also has a 1518 amino acid residue power having a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus).
- the amino acid sequence has a GPS domain and a 7-transmembrane domain (7-transmembrane domain) (see FIGS. 1A and 1B).
- This protein Compared with the amino acid sequence of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19, the amino acid sequence has 55 amino acid residues including one N-terminal TSP-I domain. It is the same except that it is deleted.
- the deleted 55 amino acid residues correspond to the 296th glycine (G) to the 350th proline (P) in the amino acid sequence of the protein represented by the amino acid sequence shown in SEQ ID NO: 20.
- Each of the three TSP-I domains is a region from the 297th histidine (His) force to the 350th proline (Pro) in the amino acid sequence shown in SEQ ID NO: 2; the 352nd glutamic acid (Glu) To the 405th proline (Pro); and the 408th aspartate (Asp) to the 461st proline (Pro).
- Each of the 7 transmembrane domains is a region from the 870th Norin (Val) force to the 890th Ferulalanin (Phe) in the amino acid sequence shown in SEQ ID NO: 2; the 899th serine (Ser ) To 919th glycine (Gly); 928th parin (Val) to 948th leucine (Leu); 970th arginine (Arg) force is also 990th threonine Area up to (Thr); 1012th alanine (Ala) force area up to 1032nd ferro-alanine (Phe); 1087th leucine (Leu) force up to 1107th alanine (Ala) Area; and the area from 1114th palin (Val) to 1134th palin (Val).
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 encodes a 1463 amino acid residue (SEQ ID NO: 16) having a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus). It consists of 4389 bp nucleotide sequence including ORF.
- Examples of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 include the protein represented by the amino acid sequence set forth in SEQ ID NO: 16.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 15 is composed of 1463 amino acid residues having a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus), The amino acid sequence has seven transmembrane domains, two TSP-I domains and one GPS domain (see Figure 1-B).
- the amino acid sequence of this protein is a residue of 110 amino acids including two N-terminal TSP-I domains. The same except that the group is deleted It is one.
- the deleted 110 amino acid residues correspond to the 296th glycine (G) to the 405th proline (P) in the amino acid sequence of the protein represented by the amino acid sequence shown in SEQ ID NO: 20.
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 encodes a 1518 amino acid residue (SEQ ID NO: 18) having a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus). It consists of 4554 bp nucleotide sequence including ORF.
- Examples of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 include the protein represented by the amino acid sequence set forth in SEQ ID NO: 18.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 17 has 1518 amino acid residues (SEQ ID NO: 18) having a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus).
- the amino acid sequence has seven transmembrane domains, three TSP-I domains, and one GPS domain (see Fig. 1B).
- the amino acid sequence of this protein includes one second TSP-I domain from the N-terminal side as compared to the amino acid sequence of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19. Identical except that 55 amino acid residues are missing.
- the 55-amino acid residue that is deleted corresponds to the 351st norrin (V) force corresponding to the 405th proline (P) in the protein represented by the amino acid sequence shown in SEQ ID NO: 20. .
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19 is referred to as the 7tmHR (seven transmem brane herix receptor) gene (GenBank, accession number: AB065648).
- This DNA consists of a 4719 bp base sequence containing an ORF encoding 1573 amino acid residues (SEQ ID NO: 20) having a signal sequence and a predicted portion (20 amino acid residues from the N-terminus).
- Examples of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19 include the protein represented by the amino acid sequence set forth in SEQ ID NO: 20.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19 is referred to as 7tm HR (GenBank, accession number: AB065648). This protein consists of 1573 amino acid residues, and its amino acid sequence has seven transmembrane domains, four TSP-I domains, and one GPS domain (see Fig. 1B).
- the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 21 is a known human DNA and is referred to as hBAI2 gene (GenBank, accession number: AB005298). This DNA consists of a 5399 bp base sequence containing an ORF encoding a 1572 amino acid residue (SEQ ID NO: 22) having a predicted sequence (20 amino acid residues from the N-terminus).
- Examples of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 21 include the protein represented by the amino acid sequence set forth in SEQ ID NO: 22.
- the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 21 is a known human protein and is referred to as hBAI2 (GenBank, accession number: AB005298). This protein also has 1572 amino acid residues, and has 7 transmembrane domains, 4 TSP-I domains, and 1 GPS domain in its amino acid sequence (see Figure 1-A). Compared with the amino acid sequence of the protein encoded by the DNA represented by the nucleotide sequence shown in SEQ ID NO: 19, the amino acid sequence of this protein has one amino acid residue corresponding to the 1461st lysine in the C-terminal region. It is the same except that it is deleted.
- the DNA represented by any one of the nucleotide sequences described in SEQ ID NOs: 1, 15, 17, 19, and 21 and the protein encoded by the DNA are thus homologous to each other. It has a TSP-I domain, a GPS domain and a 7th transmembrane domain.
- DNA represented by any one of the nucleotide sequences of SEQ ID NOs: 1, 15, 17, 19 and 21 and the protein encoded by the DNA have sequence homology and structural features. Because of the similarity of features, the inventors consider it to be a splicing noriant.
- the proteins represented by any one of the amino acid sequences have homology to each other, and the TSP-I domain, the GPS domain And preserve the 7th transmembrane domain.
- the inventors consider these proteins to be splicing variants due to sequence homology and similarity in structural features.
- the DNA gene product represented by any one of the nucleotide sequences described in SEQ ID NOs: 15, 17, and 19 actually showed a function as a membrane protein receptor.
- CCK-8S SEQ ID NO: 14
- SEQ ID NO: 14 is used in the same manner as the animal cell in which the DNA gene product represented by the nucleotide sequence shown in SEQ ID NO: 1 is expressed.
- the DNA used in the present invention is represented by the above DNA, for example, a base sequence containing at least one base sequence among the base sequences described in SEQ ID NOs: 1, 15, 17, 19 and 21. Can be DNA.
- the DNA used in the present invention is represented by a DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or a partial nucleotide sequence present in a designated region of the splicing noriant of the DNA. It can be a DNA fragment. Such a DNA fragment is useful because it can be used as a primer or probe for detecting the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or a splicing variant of the DNA, or a primer for producing this DNA. It is.
- the primer is preferably composed of 15 to 30, more preferably 20 to 25 nucleotides.
- the probe preferably consists of 8 to 50 nucleotides, more preferably 17 to 35 nucleotides, and even more preferably 17 to 30 nucleotides. If the length of the primer or probe is longer than the appropriate length, the specificity decreases due to an increase in pseudohybridization. In addition, if the length is shorter than the appropriate length, mismatch occurs and specificity decreases.
- the designated region of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or the splicing variant of the DNA includes a site that is a fragment of a protein encoded by the DNA and on which a ligand acts.
- a region encoding a fragment is preferably mentioned.
- a DNA fragment represented by a partial base sequence existing in a region encoding a fragment containing a site where a ligand acts can be used for production of a fragment containing a site where a ligand acts.
- the fragment containing the site where the ligand acts is useful for detecting the action of the ligand on the protein used in the present invention, for example, detecting the binding between the protein and the ligand, and identifying a compound that promotes or inhibits the action. Alternatively, it is useful for identifying a compound having the same action as a ligand for this protein, ie, an antigen.
- a DNA fragment also has a nucleotide strength of preferably 5 or more nucleotides, more preferably 10 or more, more preferably 20 or more nucleotides in the region as a minimum unit.
- the DNA represented by the base sequence shown in SEQ ID NO: 1 or the DNA fragment represented by the partial base sequence present in the designated region of the splicing variant of the DNA is also a sense strand encoding a protein.
- the DNA fragment is complementary to It is useful as an antisense oligonucleotide that inhibits the expression of the DNA represented by the sequence or a splicing variant of the DNA. Since it is known that the expression of a DNA fragment force gene generally consisting of about 20 nucleotides can be inhibited, the antisense oligonucleotide is preferably composed of 15 or more nucleotides, more preferably 20 or more nucleotides. Become.
- DNA fragments are designed to have a target sequence according to the nucleotide sequence information of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or the splicing variant of the DNA. Can be manufactured. It can be easily produced using an automatic DNAZRNA synthesizer.
- the protein used in the present invention is the above-mentioned protein, for example, a protein represented by an amino acid sequence containing any one of the amino acid sequences described in SEQ ID NOs: 2, 16, 18, 20, and 22. Can be.
- the protein used in the present invention may be a fragment represented by a partial amino acid sequence present in a designated region of the protein.
- the fragment of this protein is useful because it can be used as an antigen for preparing an antibody against this protein.
- the designated region of the protein to be used preferably includes a site where a ligand acts on the protein.
- the fragment containing the site where the ligand acts is useful for detecting the action of the ligand on the protein, for example, detecting the binding between the protein and the ligand, and identifying a compound that promotes or inhibits the action.
- the fragment containing the site where the ligand acts is useful for detecting the action of the ligand on the protein, for example, detecting the binding between the protein and the ligand, and identifying a compound that promotes or inhibits the action.
- fragments that inhibit the interaction between the ligand and the protein are useful as compounds that inhibit the induction of the function of the protein by the action of the ligand.
- the fragment represented by the partial amino acid sequence present in the designated region of the protein used in the present invention is preferably 5 or more, more preferably 8 or more, and further preferably 12 or more as the minimum unit. Especially preferably, it will also have a power of 15 or more consecutive amino acids. is there.
- These fragments can be produced by designing a fragment having a target sequence according to the amino acid sequence information of the present protein, for example, by a chemical synthesis method known per se.
- the protein used in the present invention may be prepared from cells or biological samples in which the gene encoding the protein is expressed by genetic engineering techniques, a cell-free synthetic product, or a chemical synthesis product. It may be further purified from these.
- the present protein can be expressed in a cell containing a gene encoding the present protein.
- the cell may be a transformant obtained by transfecting a vector containing a gene encoding this protein.
- the protein used in the present invention can be further modified as long as it does not undergo a significant change in function, such as modification of its constituent amino group or carboxyl group, for example, by amidation.
- another protein or the like is added to the N-terminal side or C-terminal side directly or indirectly by using a genetic engineering technique or the like via a linker peptide or the like. Also good.
- labeling so that the basic properties of the protein are not inhibited is desirable.
- proteins to be added include enzymes such as GST, ⁇ -galactosidase, HRP or ALP, tag peptides such as His-tag, Myc-tag, HA-tag, FLAG-tag or Xp ress-tag, fluorescein
- fluorescent dyes such as isothiocyanate (fluorescein is othiocyanate) or phycoerythrin, maltose binding protein, Fc fragment of immunoglobulin or piotin, etc. is not limited thereto. It can also be labeled with a radioisotope.
- Substances used for labeling can be added alone or in combination of two or more. By measuring the substance itself used for labeling or its function, this protein can be easily detected or purified, and for example, the interaction between the protein used in the present invention and other proteins can be detected.
- DNA used in the present invention is a known genetic engineering technique (edited by Sambrook et al., “Molecular Cloning, Laboratory Mathematic 2nd Edition”, 1989, Cold Spring Nober Laboratories; see Muramatsu, Masaaki, “Lab Manual Genetic Engineering”, Mar. 1989, Maruzen Co., Ltd.).
- the bases described in SEQ ID NO: 1, 15, 17, 19, and 21 in the sequence listing The DNA represented by the sequence can be obtained by a known genetic engineering technique based on the sequence information.
- the DNA used in the present invention can be obtained by preparing a cDNA library according to a conventional method from an appropriate source in which the expression of the present DNA has been confirmed. This can be done by selecting a desired clone using appropriate probes and primers.
- Examples of the origin of cDNA include various cells and tissues in which the expression of this DNA has been confirmed, or cultured cells derived therefrom.
- Examples of the origin of the DNA represented by the nucleotide sequence shown in SEQ ID NO: 1 and the splicing variant of the DNA include human brain tissue and brain cells.
- RNA from origin Isolation of total RNA from origin, isolation and purification of mRNA, acquisition of cDNA and its cloning, etc. can all be performed according to conventional methods.
- a cDNA library can be constructed and used from commercially available polyA + RNA derived from human brain, fetal brain, and brain hippocampus.
- a conventional method can be used. Examples thereof include a black hybridization method using a probe that selectively binds to a target DNA sequence, a colony hybridization method, and a combination of these methods.
- DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or DNA chemically synthesized based on information on the nucleotide sequence of the splicing noble of the DNA can be generally used.
- a sense primer and an antisense primer designed based on the base sequence information of this DNA can be used as such a probe.
- Selection of the target clone from the cDNA library can be performed, for example, by confirming the expressed protein for each clone using a known protein expression system and using the biological function as an index.
- PCR In addition to DNA, PCR (Ulmer, KM, Science, 1983, 219th, p. 666-671; Ehrlich, HA; edited by Ehrlich, HA; PCR technology, Principles and applications of DNA amplification ", 1989, Stockton Press; Saiki RK et al.," Science ", 1985, 230, p. 1350-1354)) Can be suitably used. Full length cDNA from cDNA library In cases where it is difficult to obtain, the RACE method ("Experimental Medicine", 1994, No.12, No.6, p. 6 15-618), especially the 5'-RACE method (Frohman MA et al.
- Primers used for PCR can be appropriately designed based on DNA base sequence information, and can be obtained by synthesis according to conventional methods. Isolation and purification of the amplified DNAZRNA fragment can be performed by a conventional method. For example, DNAZRNA fragments can be isolated and purified by gel electrophoresis.
- the base sequence of DNA can be determined by conventional methods such as the dideoxy method (“Proceedings of Tne National Academy of Sciences of Thes United States of America), 1977, 74, p. 5463-5467) and Maxam Gilbert method (Methods in Enzymology), 1980, 65th, p. 499—560 This can be carried out using a commercially available sequence kit or the like.
- the DNA is located at the 5, terminal or ⁇ terminal side, for example, gnoretathione S transferase (GST), ⁇ Enzymes such as galactosidase, horseradish peroxidase (HRP) or alkaline phosphatase (ALP), tag peptides such as His-tag, Myc-tag, HA-tag, FLAG-tag or Xpress-tag
- GST gnoretathione S transferase
- ⁇ Enzymes such as galactosidase, horseradish peroxidase (HRP) or alkaline phosphatase (ALP), tag peptides such as His-tag, Myc-tag, HA-tag, FLAG-tag or Xpress-tag
- HRP horseradish peroxidase
- ALP alkaline phosphatase
- tag peptides such as His-tag, Myc-tag, HA-tag, FLAG-tag or Xpress-tag
- the gene
- a recombinant vector containing the DNA By inserting the DNA used in the present invention into an appropriate vector DNA, a recombinant vector containing the DNA can be obtained.
- the recombinant vector is a thread-and-change vector in which the DNA is incorporated, it can be a misaligned thread-and-change vector! /.
- the vector DNA is not particularly limited as long as it can replicate in the host, and is appropriately selected depending on the type of host and intended use.
- the vector DNA may be one obtained by extracting a naturally occurring one or a part of the DNA other than the portion necessary for replication. Representative examples include vector DNA derived from plasmids, nocteriophages and viruses. Examples of plasmid DNA include plasmids derived from E.
- virus-derived vector DNA examples include vectors derived from animal viruses such as retrovirus, vaccinia virus, adenovirus, papovavirus, SV40, fowlpox virus, and pseudorabies virus, or vectors derived from insect viruses such as baculovirus.
- Other examples include vector DNA derived from transposon, insertion element, yeast chromosome element, and the like.
- vector DNA prepared by combining them for example, vector DNA prepared by combining genetic elements of plasmid and butterfly fuzzy (cosmid phage gene etc.) can be exemplified.
- an expression vector or a cloning vector may be used.
- a gene it is necessary to incorporate a gene into a vector so that the function of the target gene is exerted, and at least the target gene sequence and a promoter are its constituent elements.
- gene sequences carrying information on replication and control if desired, selected from cis-elements such as ribosome binding sequences, terminators, signal sequences, enhancers, splicing signals, and selection markers
- selection markers include dihydrofolate reductase gene, ampicillin resistance gene, neomycin resistance gene and the like.
- the target gene sequence is treated with an appropriate restriction enzyme, cleaved at a specific site, mixed with vector DNA treated in the same manner as in V, and religated by ligase.
- a desired linker can also be obtained by ligating an appropriate linker to the target gene sequence and inserting it into a multicloning site of a suitable vector. A replacement vector is obtained.
- a transformant can be obtained by introducing a vector DNA incorporating the DNA used in the present invention into a host. If an expression vector is used as the vector DNA, the present DNA can be expressed, and a protein encoded by the DNA can be produced. The transformant can be obtained by further introducing one or more vector DNAs containing a desired gene other than the present DNA.
- prokaryotes for example, Escherichia coli such as Escherichia coli, Bacillus genus such as Bacillus subtilis, Syudomonas genus such as Pseudomonas putida, Rhizobium meliloti Examples include bacteria belonging to the genus Rhizobium.
- yeasts such as Saccharomyces cerevisiae and Schizosaccharomyces pombe
- insect cells such as Sf9 and Sf21
- COS cells, Vero cells monkey kidney-derived cells
- Chinese hamsters Examples include animal cells such as ovary cells (CHO cells), mouse L cells, rat GH3 cells, human FL cells, 293 EBNA cells, and Xenopus oocytes.
- animal cells are used.
- the recombinant vector can autonomously replicate in the cell At the same time, it is preferably composed of a promoter, an RNA splice site, a target gene, a polyadenylation site, and a transcription termination sequence. Further, a replication origin may be included as desired.
- a promoter SRa promoter, SV40 promoter, LTR promoter, CMV promoter and the like can be used, and cytomegaloinores early gene promoter and the like can also be used.
- Preferable methods for introducing a recombinant vector into animal cells include, for example, the electopore position method, the calcium phosphate method, and the lipofusion method.
- the recombinant vector is capable of autonomous replication in the bacterium, and at the same time, comprises a promoter, a ribosome binding sequence, a target gene, and a transcription termination sequence.
- a gene that controls the promoter may be included.
- any promoter can be used as long as it can be expressed in a host such as Escherichia coli.
- promoters derived from Otsuki phages such as trp promoter, 1 ac promoter, PL promoter, PR promoter and the like can be exemplified.
- An artificially modified promoter such as a tac promoter may be used.
- the method for introducing the thread recombination vector into bacteria is not particularly limited as long as it is a method for introducing DNA into bacteria. Preferable examples include a method using calcium ions and an elect mouth position method.
- the promoter is not particularly limited as long as it can be expressed in yeast, and any promoter may be used.
- gall promoter, gallO promoter, heat shock protein promoter, MFa1 promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter, AOX1 promoter and the like can be exemplified.
- the method for introducing the recombinant vector into yeast is not particularly limited as long as it is a method for introducing DNA into yeast, and preferred examples include the electopore method, the sphere plaster method, and the lithium acetate method.
- examples of a method for introducing a recombinant vector preferably include the calcium phosphate method, the lipofusion method, and the electopore position method.
- a transformant obtained by transfecting a vector DNA containing the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the Sequence Listing specifically, HA-ph01207 # 1 0 — 6 cell lines.
- the HA-ph01207 # 10-6 cell line is a signal sequence (20 amino acid residues from the N-terminus of the amino acid sequence described in SEQ ID NO: 2) of the DNA ORF represented by the base sequence described in SEQ ID NO: 1.
- the HA-ph 01207 # 10-6 cell line stably expresses the N-terminal HA-tag fusion protein. A specific method for producing this cell line is described in detail in Example 2.
- the HA-ph01207 # 10-6 cell line has the accession number FERM BP-10101, the National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center (1st, Tsukuba, Ibaraki, Japan, 1st 1 The deposit was made on August 19, 2004. The existence of this cell line has been confirmed by a test conducted on September 22, 2004 at the Deposit Center.
- the protein used in the present invention can be obtained, for example, based on the base sequence information of the gene encoding this protein, based on general genetic engineering techniques (edited by Sambrook et al., “Molecular Cloning, Laboratories-2nd Edition ", 1989, Cold Spring Laboratory Laboratories; Muramatsu, Masami,” Laboru-Mual Genetic Engineering “, 1988, Maruzen Corporation; Ulmer, KM,” Science ), 1983, 219, p. 666-671; edited by Ehrlich, HA; "PCR Technology, Principles and Applications of DNA Amplification", 1989, Stockton Press, etc.) .
- a cDNA library is prepared from various cells and tissues in which expression of the gene encoding this protein has been confirmed, or cultured cells derived from these cells, for example, human brain tissue, according to a conventional method.
- the gene can be obtained by amplifying the gene using an appropriate primer and inducing the expression of the obtained gene by a known genetic engineering technique.
- a trait obtained by transfection of a vector DNA containing the above DNA The protein can be produced by culturing the transformant and then recovering the target protein from the resulting culture.
- the transformant can be cultured using culture conditions and culture methods known per se optimal for each host. Culturing can be performed using the present protein expressed by the transformant itself or its function as an index. Alternatively, subculture or batch culture may be performed using as an index the amount of transformant in the medium which may be cultured using the present protein itself or the amount of the protein produced in or outside the host as an index. .
- the target protein When the target protein is expressed in the cell or on the cell membrane of the transformant, the target protein is extracted by crushing the transformant. When the target protein is secreted outside the transformant, use the culture solution as it is or use a culture solution from which the transformant has been removed by centrifugation or the like.
- the protein used in the present invention can also be produced by a general chemical synthesis method.
- solid phase synthesis methods and liquid phase synthesis methods are known as chemical protein synthesis methods, and any of them can be used. More specifically, such a protein synthesis method is based on the amino acid sequence information! Then, each amino acid is sequentially linked one by one to extend the chain! The so-called stepwise longong method And a fragment condensation method in which a fragment having several amino acids is synthesized in advance and then each of the fragments is subjected to a coupling reaction, and the protein can be synthesized by any of them.
- Condensation methods used in the above protein synthesis can also follow conventional methods such as azide method, mixed acid anhydride method, DCC method, active ester method, redox method, DPPA (diphenylphosphoryl azide) method, DCC + Additional products (1-hydroxybenzotriazole, N-hydroxysuccinamide, N-hydroxy-1,5-norbornene-1,2,3-dicarboximide, etc.) method, Woodward method, etc. can be exemplified.
- the protein obtained by chemical synthesis can be further appropriately purified according to various conventional purification methods as described above.
- the protein used in the present invention can be fragmented by cleaving with an appropriate peptidase, and as a result, a fragment of this protein can be obtained.
- Proteins can be purified and Z or separated by various separation methods utilizing their physical properties, chemical properties, etc., if desired. Separation and Z or purification can be performed using the function of the protein as an index. For example, ammonium sulfate precipitation , Ultrafiltration, gel chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography, dialysis, etc. can be used alone or in appropriate combination.
- a specific antibody against them is prepared and specifically adsorbed using the antibody, for example, affinity chromatography using a column to which the antibody is bound. Recommended to use.
- an antibody against the protein can be prepared.
- the protein or fragment thereof used as an antigen is composed of at least 8, preferably at least 10, more preferably at least 12, even more preferably 15 or more amino acids.
- the amino acid sequence of this region does not necessarily need to be homologous or identical to that of the protein or fragment thereof used in the present invention. Even if the primary structure is discontinuous, the exposed site may be a continuous amino acid sequence.
- the antibody is not particularly limited as long as it specifically binds or recognizes the protein and Z or a fragment thereof used immunologically in the present invention. The presence or absence of this binding or recognition can be determined by a known antigen-antibody binding reaction.
- an antibody production method known per se can be used for antibody production.
- an antibody can be obtained by administering an antigen to an animal alone or in combination with a carrier in the presence or absence of an adjuvant and inducing immunity such as a humoral response and Z or cellular response.
- the carrier is not particularly limited as long as the carrier itself does not exert a harmful effect on the host and enhances the antigenicity, and examples thereof include cellulose, polymerized amino acid, albumin and keyhole limpet hemocyanin.
- Adjuvants include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), Ribi (MPL), Ribi (TDM), Ribi (M + Ding 0] ⁇ ), pertussis cutin (80 (16 611 & pertussis vaccine), Muramiruj Peptide (MDP), aluminum adjuvant (ALUM), and combinations thereof can be exemplified, and mice, rats, rabbits, goats, horses, etc. are preferably used as immunized animals.
- FCA Freund's complete adjuvant
- FIA Freund's incomplete adjuvant
- MPL MPL
- TDM Ribi
- M + Ding 0] ⁇ pertussis cutin
- MDP Muramiruj Peptide
- ALUM aluminum adjuvant
- Polyclonal antibodies can be obtained from the sera of animals administered with an antigen by a known antibody recovery method.
- immunoaffinity chromatography is used as an antibody recovery means.
- a monoclonal antibody collects antibody-producing cells (for example, spleen or lymphocyte-derived lymphocytes) from an animal to which an antigen has been administered, and is known per se (eg, P3-X63-Ag8). It can be produced by introducing transformation means using a myeloma strain. For example, a hybridoma is produced by fusing antibody-producing cells and permanently proliferating cells by a method known per se, and then cloned to select a hybridoma that produces an antibody that specifically recognizes the protein used in the present invention. Then, the antibody is recovered from the culture medium of the hybridoma.
- antibody-producing cells for example, spleen or lymphocyte-derived lymphocytes
- P3-X63-Ag8 lymphocyte-derived lymphocytes
- a polyclonal antibody or a monoclonal antibody capable of recognizing and binding to the protein used in the present invention can be used as an antibody for purifying the protein, a reagent, a marker marker, or the like.
- an antibody that inhibits the function of the protein, or an antibody that binds to the protein and exhibits a ligand-like action of the protein can be used to regulate the function of the protein.
- These antibodies are useful for elucidation, prevention, amelioration, and Z or treatment of various diseases caused by abnormalities of the protein and its functions.
- the protein used in the present invention is a protein that functions as a membrane protein receptor, and was able to induce a cellular response by CCK 8S (SEQ ID NO: 14) when expressed in animal cells. That is, CCK-8S (SEQ ID NO: 14) is one of the ligands of the membrane protein receptor that also has the power of this protein.
- a membrane protein receptor comprising the present protein may be referred to as a membrane protein receptor according to the present invention.
- the cell response elicited by CCK-8S (SEQ ID NO: 14) in an animal cell expressing the protein used in the present invention is specifically described in SEQ ID NO: 1 in the sequence listing. This was observed in the HA-ph01207 # 10-6 cell line in which the DNA represented by the nucleotide sequence was stably expressed. More specifically, in the HA-ph01207 # 10-6 cell line, an increase in intracellular calcium concentration was observed by the action of CCK 8S (SEQ ID NO: 14). (See Example 5). The degree of increase of intracellular calcium concentration in the cell line by InM CCK-8S (SEQ ID NO: 14) was almost the same as that by the positive control calcium ionophore A23187.
- CCK 8S Nonsulfated form
- CCK-8S did not respond to the tetrapeptide (CCK-4), which has amino acid residue strengths up to the fourth. Specifically, the increase in intracellular calcium concentration by InM CCK-8NS or InM CCK 4 was not observed. From these results, it was found that the HA-phOl 207 # 10-6 cell line specifically responds to CCK-8S (SEQ ID NO: 14) and functions as a membrane protein receptor.
- Induction of a cellular response by CCK-8S is also the DNA represented by the base sequence described in SEQ ID NO: 15, the DNA represented by the base sequence described in SEQ ID NO: 17, or the sequence It was observed in any of the cells in which the DNA represented by the nucleotide sequence of No. 19 was expressed. More specifically, in these cells, an increase in intracellular calcium concentration was observed due to the action of InM CCK-8S (SEQ ID NO: 14) (see Example 8).
- DNA represented by the base sequence described in SEQ ID NO: 15 DNA represented by the base sequence described in SEQ ID NO: 17, or DNA represented by the base sequence described in SEQ ID NO: 19
- CHO-K1 cells not expressed such an increase in intracellular calcium concentration due to CCK-8S (SEQ ID NO: 14) was not observed.
- the protein encoded by the DNA represented by any one of the nucleotide sequences selected from the nucleotide sequences set forth in SEQ ID NOs: 1, 15, 17, and 19 has an N-terminal fragment in its amino acid sequence. Forces with different numbers of repeats in the TSP-I domain in the extracellular region The amino acid sequences other than the domain are almost identical (Fig. 1-B).
- the nucleotide sequence shown in SEQ ID NOs: 1, 15, 17, and 19 is also selected! / ⁇ or either of the cells expressing the DNA represented by the nucleotide sequence of 1! / ⁇ is CCK 8S (sequence No. 14) cell response was elicited (Example 5, Example 8 and Example 9).
- CCK-8S (SEQ ID NO: 14) is at a low concentration of InM, and is represented by the HA-ph01207 # 10-6 cell line and the nucleotide sequence shown in SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19.
- CCK-8S (SEQ ID NO: 14) actually induced a cellular response in vivo via the protein encoded by the DNA. Conceivable. That is, the inventors consider that CCK-8S (SEQ ID NO: 14) is one of the in vivo ligands of the functional membrane protein receptor according to the present invention, which is expected to be GPCR. In addition, this membrane protein receptor showed a cellular response such as changes in membrane potential in Xenopus oocytes when HeLa cell culture supernatant was used as a ligand source.
- the range of ligands of the membrane protein receptor according to the present invention includes one to several amino acids in the amino acid sequence of CCK 8S (SEQ ID NO: 14). Peptides having amino acid sequence ability having mutations such as deletion, substitution, addition or insertion and having the same function as CCK-8S are included. “Functional equivalent to CCK-8S” means a function of inducing the biological function of the membrane protein receptor according to the present invention, more specifically, in a cell expressing the membrane protein receptor, A function that induces cellular responses such as an increase in internal calcium concentration and changes in membrane potential.
- CCK-8S (SEQ ID NO: 14) is sulfated with the 7th tyrosine residue from the C-terminal. Therefore, it is preferable that the sulfated tyrosine residue is conserved in the ligand of the present membrane protein receptor.
- Proteins with mutations are naturally occurring, for example, due to mutations or post-translational modifications. It may also be obtained by introducing mutations based on naturally derived genes. Means for introducing a mutation are known per se, and the above-described method can be used.
- homologous amino acids polar amino acids, nonpolar amino acids, hydrophobic amino acids, hydrophilic amino acids
- Positively charged amino acids, negatively charged amino acids and aromatic amino acids etc. are easily envisaged.
- Peptides are also included in the range of ligands of the membrane protein receptor. In such a peptide, it is preferable that a seventh sulfate synthase residue present from the end of 1 ⁇ 83 is retained.
- CCK tissue expression is abundant in brain tissues, particularly in the cerebral cortex, hippocampus, amygdala, and hypothalamus (see Table 3).
- tissue expression of DNA encoding the protein used in the present invention is remarkably strongly observed in the cerebral cortex, hippocampus and amygdala (see Example 10 and Table 3). reference).
- the inventors of the present invention believe that the ligand of this membrane protein receptor is CCK, for example, CCK 8S (SEQ ID NO: 14). Is thinking.
- CCK-8S SEQ ID NO: 14
- CCK-8S SEQ ID NO: 14
- the membrane protein receptor according to the present invention is involved in the neurological function such as retention of the protein. Decreased or disappearance of CCK-8S (SEQ ID NO: 14), Z, or function causes pathological symptoms such as difficulty in bringing memory back to consciousness and putting it into action.
- the present inventors consider that the action of CCK-8S (SEQ ID NO: 14) on such nerve function is mediated by the present membrane protein receptor. Therefore, diseases and symptoms associated with such impaired memory function can be alleviated by the membrane protein receptor agonist. Examples of such diseases include diseases associated with impairment of neurological functions such as memory, such as dementia and Arnotnoima disease.
- CCK has been involved so far, anxiety, analgesia, sedation, suppression of eating
- the membrane protein receptor is involved as a CCK receptor in physiological functions such as regulation, memory, and learning.
- CCK has been reported to exhibit a number of actions in the extinct organs and is thought to be a signal substance that gives the brain a sensation of fullness.
- CCK-8S a family of CCK, also acts as a signal substance that gives the brain fullness.
- the inventors believe that the quantitative and functional decline of CCK-8S causes obesity due to reduced satiety.
- the present inventors consider that the present membrane protein receptor is involved in such obesity as a CCK receptor.
- agonists and antagonists for this membrane protein receptor can alleviate diseases and symptoms associated with such impaired physiological functions. That is, the agonists and antagonists for this membrane protein receptor can be used as an anxiolytic, an analgesic, or an active ingredient for prevention and Z or treatment of diseases caused by various central nervous system abnormalities. . Specific examples of such diseases include diseases such as dementia, Parkinson's disease, panic syndrome, drug addiction, obesity, and diabetes.
- the present inventors consider that the present membrane protein receptor is involved in neurological diseases such as depression, from the expression of DNA encoding the receptor protein.
- depression also called depression, is an emotional disorder such as feelings of sadness, thought disorder such as thought restraint, reduced motivation, behavioral depression, sleep disorder, circadian variation in depression, etc. Sexual disorder.
- the cause of depression is said to be a decrease in neurotransmitters in the brain.
- the onset is related to biological factors, psychological factors, and social and environmental factors.
- “Depressed state” means symptoms generally observed in depression, such as emotional disorder such as sadness, thought disorder such as thought suppression, reduced motivation, behavioral suppression, sleep disorder and the like.
- amygdala As described above, strong expression of DNA encoding the protein used in the present invention was observed in the cerebral cortex, hippocampus, and amygdala (see Example 10 and Table 3). There are reports that the amygdala is involved in depression (Whalen PJ et al., “Seminars in Clinical Neuropsychiatry”, 2002, 7th, 4th, p. 234—242; Drevets WC et al., “Annals of the New York Academy of Sciences”, 2003, No. 985, p. 420—44 4 Nestler EJ et al., “Neuron”, 2002, 34, No. 1, p. 13-25).
- the BAI2 gene is a splicing variant of DNA encoding the protein used in the present invention.
- the tail suspension test is a commonly used test method for investigating the phenotype of depression, and is used as a test system for investigating relevance to depression, such as the evaluation of antidepressants.
- Ste ru L. et al. “Psychopharmacology (Berl)”, 1985, 85th, No. 3, p. 367-370; Crowley JJ et al., “Pharmacology Neuokestry Pharmacological Biochemical Behavior, 2004, 78th, No. 2, p. 269—274; -—Nielsen DM et al., “European Journal of Phar macology” ”, 2004, No. 499, No. 1-2, p. 135-146).
- BAI2 gene knockout mice the BAI2 gene and its splicing variants are not expressed because the BAI2 gene is disrupted. That is, in mice lacking the gene product of BAI2 gene and its splicing variant, antidepressant The state was induced. From these results, the inventors believe that the gene product of the BAI2 gene and its splicing variant are involved in depression.
- the inventors consider that the BAI2 gene and its splicing variants, that is, the DNA encoding the protein used in the present invention and its splicing variants are involved in depression.
- CCK-A receptor also called CCK1 receptor
- CCK-B receptor also called CCK2 receptor
- This membrane protein receptor differs from CCK-A receptor and CCK-B receptor due to different ligand affinity and expression distribution compared to CCK A receptor and CCK B receptor The inventors believe that they are responsible for physiological effects. Specifically, this membrane protein receptor is similar in ligand affinity to CCK-A receptor but has a different expression distribution, and similar in expression distribution to CCK-B receptor, but has ligand affinity. Is different.
- the membrane protein receptor comprising the protein since the expression of DNA encoding the protein used in the present invention is specifically elevated in the brain thread and tissue, the membrane protein receptor comprising the protein has a low CCK A expression in brain tissue. The inventors consider that they are involved in the action of CCK in the central nervous system compared to receptors. In addition, since the ligand affinity is different from that of CCK-B receptor expressed in brain tissue, the membrane protein receptor according to the present invention exhibits physiological activity different from that of CCK B receptor in the brain. The inventors are thinking.
- the membrane protein receptor was observed to be in an antidepressant state in knockout mice of the gene.
- phenotypes of CCK-A receptor gene knockout mice, CCK B receptor gene knockout mice, and CCK A receptor gene and CCK B receptor gene double knockout mice have been reported.
- B receptor gene knockout mice have been reported to have increased behavioral activity! /, And! / ⁇ , but there is no report showing a relationship between these knockout mice and depression.
- This membrane protein receptor, CCK A receptor and CCK B receptor are all CCK Based on the tissue expression distribution and the phenotype of knockout mice, the present inventors consider that only the membrane protein receptor is a membrane protein receptor associated with depression. Furthermore, since CCK-A receptor has low expression in brain tissue, it is considered not to be involved in the physiological activity of CCK in brain tissue. Although the CCK-B receptor is expressed in brain tissue, there are no reports suggesting an association between the phenotype of a knockout mouse gene encoding the CCK B receptor protein and depression.
- the CCK A receptor is strongly expressed mainly in the extinct organs and is partially expressed in brain tissue.
- the ligand affinity of CCK-A receptor is strong in the order of CCK-8S>> CCK-8NS and gastrin> CCK-4.
- the CCK-A receptor responds strongly to CCK-8S (SEQ ID NO: 14), but the specificity of the CCK A receptor for the ligand is not observed.
- CCK B receptors are widely expressed in brain tissues in addition to the extinct organs.
- CCK-8S ⁇ CCK-8NS, gastrin> Selectivity is lower than CCK A receptor, which is stronger in the order of CCK4.
- the phenotype of CCK-A receptor knockout mice includes abnormalities in homeostasis such as thermoregulation as well as abnormalities in the digestive system such as abnormalities such as gallstones, spleen enzyme secretion and gallbladder contraction ( Nomoto S. et al., “American Journal of Physiology, Legacy and Integrative and Comparative Physiology ⁇ American journal of physiology. Regulatory, integrative and comparative physiology”, 2004, No. 287, No. 3, R556—61), increased behavioral activity (Miyasaka K. et al., “Neuroscie nce Letters”, 2002, No. 335, No. 2, p. 115—118), and appetite Abnormal regulation (Bi S. et al., “Neuropeptides”, 2002, Vol. 36, No. 2-3, p. 171-181) has been reported.
- CCK B receptor knockout mice have phenotypes related to central system phenotypes such as anxiety, pain and memory, as well as abnormalities in the gastrointestinal system such as abnormal gastric acid secretion and malformation of the gastric mucosa.
- central system phenotypes such as anxiety, pain and memory, as well as abnormalities in the gastrointestinal system such as abnormal gastric acid secretion and malformation of the gastric mucosa.
- abnormalities in the gastrointestinal system such as abnormal gastric acid secretion and malformation of the gastric mucosa.
- There are many reports such as reports (Noble F. et al., “Neuropeptides”, 2002, Vol. 36, No. 2-3, p. 157-170). More specifically, suppression of anxiety behavior (Horinouchi Y. et al. European Neuropsychopharmacology, 2004, 14th, No. 2, p. 157-161), increased anxiety behavior (Miyasaka K. et al., “Neuroscience Letters”)
- the inventors consider that the DNA encoding the protein used in the present invention, that is, the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 and the splicing variant of the DNA are involved in depression. Yes.
- the inventors consider that depression and depression are induced by abnormalities when the expression of the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 or the splicing variant of the DNA increases.
- the protein encoded by the DNA and the splicing of the protein Inhibition of the function and Z or expression of any one of the proteins selected from the group force consisting of a variant can improve the depression and recover from depression.
- the present invention relates to a function of any one of the proteins selected from the group consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein, and Z Alternatively, the present invention relates to a method for improving a depressive state by inhibiting expression.
- Immulating depression refers to depression compared to before the method of improving depression is implemented. One condition is alleviated or restored. For example, it means that emotional disorder, thinking disorder, decreased motivation, behavioral inhibition, sleep disorder, etc. are reduced or recovered.
- the function and Z or expression of the protein used in the present invention can be inhibited by, for example, a compound that inhibits the function and Z or expression of the protein.
- the terms “compound inhibiting the function of the protein used in the present invention” and “antagonist of the present protein” are used interchangeably.
- the “antagonist” may be a compound that inhibits the function of the protein used in the present invention. For example, it binds to a receptor and inhibits the effect of an agonist, but itself binds to the receptor.
- compounds that cannot exhibit the effects exhibited by agonists include compounds, compounds that inhibit ligand binding to receptors, or compounds that act as inverse agonists (inverse agonists) on this protein.
- a receptor such as GPCR is converted from an active form to an inactive form or from an inactive form to an active form regardless of the action of the ligand.
- a substance such as a GPCR that inhibits a process in which an inactive force is converted into an active form regardless of the action of a ligand is called an inverse agonist. It is considered that the inverse virus of this protein also inhibits the function of the protein used in the present invention.
- the protein antagonist used in the present invention binds to a membrane protein receptor that also has the ability of the protein to inhibit the effect of the ligand. It is thought that depression and depression are induced by abnormalities such as increased expression of the DNA encoding this protein. Therefore, the antagonist of this protein inhibits the action of the ligand on the receptor of this protein. For example, the inventors believe that depression and depression can be improved.
- the protein antagonist used in the present invention is considered to have an antidepressant action.
- Antidepressive action means an effect of improving a depressive state.
- the compound that inhibits the function of the protein used in the present invention is preferably an antagonist that inhibits the function caused by CCK-8S in the membrane protein receptor that also has the ability of the protein. Is preferred.
- the antagonist can be an antagonist that inhibits a function caused by a peptide having the same function as CCK-8S in a membrane protein receptor having the ability of the protein.
- the protein antagonist used in the present invention can be obtained by the compound identification method described below.
- the ligand of the membrane protein receptor consisting of this protein is a protein
- a substance that is a partial peptide of the ligand and binds to the membrane protein receptor but cannot exert the effect exhibited by the ligand. Can be used.
- the partial peptide of the membrane protein receptor ligand is synthesized by designing a number of partial peptides from the amino acid sequence, and the synthesized partial peptide force is also antagonized by the compound identification method described below. It can be obtained by selecting one having activity as a strike.
- Examples of protein antagonists used in the present invention include three types of compounds (formulas (I), (II), and (iii)) identified by the compound identification method described later (see Example 12).
- a group force consisting of a protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and a splicing variant of the protein is also selected. It is possible to provide an agent for improving depression including a compound that inhibits protein function and Z or expression. Hereinafter, an agent for improving depression is sometimes referred to as an antidepressant.
- Depressant improving agent or “antidepressant” means an agent that has the effect of improving the depressed state.
- a method for identifying a compound that inhibits the function of the protein used in the present invention is described in the present protein. It can be carried out using a pharmaceutical screening system known per se, using at least one of DNA, a recombinant vector, a transformant and an antibody.
- identification method selection of antagonists by drug design based on the three-dimensional structure of the protein, selection of inhibitors or promoters of expression at the gene level using protein synthesis systems, or antibody recognition substances using antibodies Sorting can be performed.
- the method for identifying a compound that inhibits the function of a protein used in the present invention can be used as a method for identifying a compound having an antidepressant action. More preferably, in the present identification method, the group of the protein consisting of the protein represented by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1 in the sequence listing and the splicing variant of the protein is also selected. It can be used as a method for identifying a compound having an antidepressant action, which is an antagonist. Confirmation of the ability of the compound to exhibit an antidepressant action can be performed using a commonly used test method for antidepressant action, such as a tail suspension test or a forced swimming test using mice.
- a commonly used test method for antidepressant action such as a tail suspension test or a forced swimming test using mice.
- the compound when the compound is administered to mice and the immobility time is shortened in the tail suspension test compared to mice not administered with the compound, the compound exhibits an antidepressant action. It can be determined that it has. Such a compound is useful as an antidepressant.
- the identification of a compound that inhibits the function of the protein used in the present invention can be carried out using, for example, an experimental system that can measure the function of the protein.
- the function of the protein and the test compound is measured under the condition that enables the interaction between the protein and the compound to be examined (hereinafter referred to as the test compound).
- the present identification method can be carried out by detecting a change (reduction, increase in calorie, disappearance or appearance) of the protein function in comparison with the measurement result in the absence of the test compound.
- the function of this protein in the presence of the test compound with the function of the protein in the absence of the test compound, the effect of the test compound on the function of the protein can be determined. .
- the test compound will contain the protein. It can be determined that there is an action that inhibits the function of.
- the protein used in the present invention functions as a membrane protein receptor, it binds to a ligand, activates an intracellular signal transduction mechanism, and induces a cellular response.
- a ligand binds to a ligand, activates an intracellular signal transduction mechanism, and induces a cellular response.
- examples include binding to CCK-8S (SEQ ID NO: 14) and interaction with MAGUK family 1 related protein.
- a method for identifying a compound that inhibits the binding between a protein and a ligand of the protein used in the present invention comprises reacting the protein and the ligand of the protein in the presence and absence of a test compound, It can be carried out by measuring the binding between the ligand and the ligand.
- the protein used in this identification method can be a protein expressed on the cell membrane of a cell containing DNA encoding the protein.
- the cell may be a transformant obtained by transfection with a vector containing DNA encoding the present protein.
- the measurement of the binding between this protein and the ligand of the protein can be carried out using various binding analysis methods used in general pharmaceutical screening systems.
- a binding reaction between the ligand and the protein is performed, and a complex formed by the binding of the protein and the ligand is separated from an unbound free ligand and the protein.
- the detection can be carried out by a known method such as lotting.
- the binding can be measured by conducting a binding reaction between the ligand and the protein, and then measuring the ligand bound to the protein using an anti-ligand antibody.
- the anti-ligand antibody bound to the ligand can be detected by using a secondary antibody labeled with HRP or piotin. It is also possible to detect the ligand bound to this protein using an anti-ligand antibody labeled with HRP or piotin.
- the ligand is used for the binding reaction with the present protein, and the ligand is labeled with a desired labeling substance.
- the identification method is performed, and the labeling substance is detected to bind to the protein.
- the measured ligand can be measured.
- Any of the substances used in general binding analysis methods can be used as the labeling substance, such as GST, His-tag, Myc-tag, HA-tag, FLAG-tag or Xpress-tag, or other peptide peptides, Examples include fluorescent pigments.
- a radioisotope element can be used.
- the present protein is a membrane protein receptor
- the compound obtained by the method for identifying a compound that inhibits the binding between the protein used in the present invention and a ligand of the protein has a function of the present membrane protein receptor. It may be a compound that inhibits
- the compound that inhibits the binding of the protein used in the present invention to the ligand of the protein and inhibits the function of the membrane protein receptor comprising the protein is an antagonist of the membrane protein receptor.
- Can be used as a strike. Whether or not the compound is a compound that inhibits the function of the membrane protein receptor according to the present invention is determined by the function of the membrane protein receptor caused by a ligand in the presence and absence of the compound. Can be determined by measuring the change in. When the compound does not change the function of the membrane protein receptor, the compound binds to the membrane protein receptor but does not induce a cellular response via the membrane protein receptor. It can be determined that the compound acts to inhibit the binding between the ligand and the membrane protein receptor.
- the compound can accept the membrane protein receptor. It is determined to be an agonist that binds to the body and induces a cellular response via the membrane protein receptor.
- the method for measuring the function of the protein can be used to implement a method for identifying a compound that inhibits the function of the protein, for example, the activity of the intracellular signal transduction mechanism or the induction of a cellular response.
- a compound that inhibits the function of the protein can be selected by detecting a change in function (reduction, increase in calorie, disappearance, or appearance) in comparison with the measurement result in the absence of the test compound. Examples of changes in cell response generated in transformants expressing this protein include changes in cell membrane potential and changes in intracellular calcium concentration. When a test compound causes a change such as a change in the cell membrane potential of the transformant or a decrease in intracellular calcium concentration, the test compound inhibits the function of the protein. Can be judged.
- Measurement of changes in cell membrane potential and intracellular calcium concentration can be performed using known methods.
- the function of this protein can be measured by measuring the interaction with the MAGUK family-related protein.
- the change in the interaction with the MAGUK family-related protein and the change in the binding with the G protein can be measured by well-known methods. This can be done using
- a vector containing the DNA represented by the nucleotide sequence of SEQ ID NO: 1 in the sequence listing Using an experimental system in which cell responses were measured using cells transfected with (1), a compound showing an inhibitory effect on the cell responses was identified (see Example 12). In this experimental system, CCK-8S was allowed to act on the cells to induce a cellular response, and the cellular response was measured by measuring changes in intracellular calcium concentration. As a test compound, a compound library Soft Focus GC Target Directed Fiber ( ⁇ Focus LrPCR Target-Directed Library ⁇ BioFocus) was used. As a result, three types of compounds that inhibit the cellular response of the cells to CCK-8S were identified (the above formulas (1), ( ⁇ ), and (III)). The present inventors consider that these compounds act as antagonists of the protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- a method for identifying a compound that can affect the interaction between the protein used in the present invention and the MAGUK family-related protein is, for example, a known method using the isolated present protein and the MAGUK family-related protein. This can be carried out by detecting the binding of this protein and the MA GUK family-related protein by the protein binding analysis method.
- a MAGUK family-related protein is expressed as a GST-tag fusion protein by genetic engineering techniques, then bound to dartathione sepharose, and the amount of the protein that binds to the protein is determined by, for example, an antibody against the protein, for example, Quantification is possible using antibodies labeled with enzymes such as HRP and ALP, radioactive isotopes, fluorescent dyes or piotin. Alternatively, if this protein fused with a tag peptide is used, it can be quantified using an anti-tag antibody. Of course, the present protein may be directly labeled with the above enzyme, radioisotope, fluorescent dye, piotin and the like.
- a secondary antibody labeled with the above enzyme, radioisotope, fluorescent dye, piotin or the like may be used.
- the DNA encoding this protein and the DNA encoding the MAGUK family-related protein can be co-expressed using appropriate cells, and the interaction between the two can be measured by detecting the binding between them using a pull-down method.
- a method for identifying a compound that affects the interaction between a protein used in the present invention and a MAGUK family-related protein is also exemplified by, for example, using a two-hybrid method to bind the protein to DNA.
- Plasmids that express proteins as fusion proteins, plasmids that express MAGUK family-related proteins and transcription activation proteins as fusion proteins, and plasmids that contain reporter genes such as lacZ connected to appropriate promoter genes The expression level of the reporter gene when introduced into a cell or the like and coexisting with the test compound can be compared with the expression level of the reporter gene in the absence of the test compound.
- the test compound When the expression level of the reporter gene in the presence of the test compound is reduced compared to the expression level of the reporter gene in the absence of the test compound, the test compound is associated with the protein and the MAGUK family. It can be determined that there is an action of inhibiting the binding with protein.
- the expression level of the reporter gene in the presence of the test compound is increased compared to the expression level of the reporter gene in the absence of the test compound, the test compound contains It can be determined that the binding to MAGUK family-related proteins is stable.
- identification of a compound that affects the interaction between the protein used in the present invention and the MAGUK family-related protein can also be carried out using a surface plasmon resonance sensor such as the BIACORE system. .
- the identification of the compound that affects the interaction between the protein used in the present invention and the MAGUK family-related protein is also performed by the scintillation proximity assay (SPA) method. It can be carried out by using a method applying the fluorescence ⁇ (Fluorescence resona nce energy transfer, FRET).
- SPA scintillation proximity assay
- MAGUK family-related protein used in the identification method according to the present invention include DLG2, DLG3 and DLG4, AIP1, and MAGI3.
- the MAGUK family-related protein may be partially deleted or added with a labeling substance such as another protein as long as the interaction with the protein used in the present invention is not affected. Oh ,.
- a method for identifying a compound that inhibits the expression of a protein used in the present invention is performed by using at least one of the present DNA, a recombinant vector, and a transformant. It can be implemented using a drug screening system.
- the method for identifying a compound that inhibits the expression of a protein used in the present invention can be used as a method for identifying a compound having an antidepressant action. That is, the compound obtained by this identification method can be used as an antidepressant because it is considered to have an antidepressant action.
- the method for identifying a compound that inhibits the expression of a protein used in the present invention is a method in which the expression of the DNA is measured in the experimental system capable of measuring the expression of the DNA in the coexistence of the DNA and the test compound. Subsequently, it can be carried out by detecting a change in expression (reduction or disappearance) in comparison with the measurement result in the absence of the test compound.
- Expression can be measured by direct detection of a protein encoded by DNA, for example, by introducing a signal serving as an expression index into an experimental system and detecting the signal.
- tag peptides such as ⁇ GST, His-tag, Myc-tag, HA-tag, FLAG-tag, and Xpress-tag, or fluorescent dyes can be used.
- a method for identifying a compound that inhibits the expression of a protein used in the present invention is specifically described in an experimental system in which the present protein is expressed using a transformant obtained by transfecting an expression vector containing the DNA. After the transformant and the test compound are contacted, the expressed protein can be measured. A compound that inhibits the expression of this protein can be selected by detecting a change in expression (reduction or disappearance) in comparison with the measurement result in the absence of the test compound. The presence or absence or change of protein expression can be detected by a known protein detection method such as Western blotting.
- the presence / absence or change of protein expression can be detected by detecting the biological function of the expressed protein, the cellular response via the protein, for example, the interaction with the MAG UK family-related protein that occurs when a ligand is applied. It can be carried out using various indicators such as action, changes in cell membrane potential, and changes in intracellular calcium concentration.
- a method for identifying a compound that inhibits the expression of a protein used in the present invention also includes, for example, a vector in which a reporter gene is linked in place of the DNA downstream of the promoter region of the gene containing the DNA. This can be carried out by contacting a test compound with a cell into which the vector has been introduced, for example, a eukaryotic cell, and the like, and measuring the presence or absence and change of the reporter gene.
- reporter gene reporter assembly
- the gene used can be used, for example, a gene having an enzyme activity such as luciferase, 13-galatatosidase, or chloramphie-coal acetyltransferase.
- the expression of the reporter gene can be detected by detecting the activity of the gene product, for example, the enzyme activity in the case of the reporter gene exemplified above.
- a method for identifying a compound that promotes the function or expression of the protein used in the present invention can be carried out. For example, using an experimental system that measures the binding of the protein to the ligand of the protein, a method for measuring the function of the protein, and an experimental system that measures the binding of the protein to a MAGUK family-related protein, Methods for identifying compounds that promote function can be implemented. In addition, using an experimental system capable of measuring the expression of DNA used in the present invention, a method for identifying a compound that promotes the expression of the present protein can be carried out. In such an experimental system or measurement system, when the function or expression of the present protein is increased or generated by the test compound, it can be determined that the test compound promotes the function or expression of the present protein.
- the membrane protein receptor agonist identification method of the present invention can be carried out by utilizing an experimental system or a measurement system used in the above identification method.
- a method for identifying an agonist of a membrane protein receptor according to the present invention for example, in an experimental system using a transformant expressing the present protein, after contacting the transformant with a test compound, or Examples thereof include a method including measuring a functional change occurring in a transformant in the presence of a test compound.
- the membrane protein receptor agonist is selected by detecting changes in the function of the membrane protein receptor in comparison with the measurement results in the absence of the test compound, for example, reduction, increase in calorie, disappearance, appearance, etc. it can.
- an agonist can be selected by measuring a change in function of the membrane protein receptor by a ligand of the present membrane protein receptor, such as CCK 8S (SEQ ID NO: 14), and comparing the change with the change in function.
- the antigen is preferably a compound that brings a functional change to the membrane protein receptor that is the same as the functional change caused to the membrane protein receptor by a ligand, for example, CCK 8S (SEQ ID NO: 14).
- the functional change that occurs in the membrane protein receptor by an agonist is significantly different from the functional change that occurs in the membrane protein receptor by a ligand, for example, CCK 8S (SEQ ID NO: 14). May be.
- the functional change that occurs in the membrane protein receptor by an agonist is the ligand
- CCK 8S may be weaker than the functional change that occurs in the membrane protein receptor. It is preferable to select an agent that causes an equivalent functional change. Changes in the function of the membrane protein receptor can be measured using changes in cell response via the membrane protein receptor of the transformant as an index. Therefore, a functional change of the same quality as that of the membrane protein receptor caused by a ligand such as CCK 8S (SEQ ID NO: 14) is, for example, an increase in intracellular calcium concentration via the membrane protein receptor in a transformant. It is done. Measurement of changes in intracellular calcium concentration can be performed using a well-known method (see Example 5).
- a functional change that is the same as the functional change that occurs in the membrane protein receptor by a ligand such as CCK-8S (SEQ ID NO: 14) includes a change in membrane potential through the membrane protein receptor in a transformant. Measurement of changes in membrane potential can be performed using well-known methods (see Example 3).
- the ligand either a sample containing the ligand or the ligand itself obtained by the above-described ligand identification method can be used. Since CCK-8S (SEQ ID NO: 14) is considered to be an in vivo ligand of this protein, it is preferable to use CCK-8S (SEQ ID NO: 14) as a ligand.
- CCK-8S (SEQ ID NO: 14) can be produced by a general chemical synthesis method. It can also be synthesized by a commercially available peptide synthesizer.
- the method for identifying the membrane protein receptor agonist according to the present invention comprises using the identification method described above for the complex obtained by the method for identifying a compound that binds to the membrane protein receptor. It can also be performed by determining whether to induce a change in the function of the receptor.
- the identification method By using an experimental system or a measurement system used in the above identification method, it is possible to identify a ligand of a membrane protein receptor having a protein power used in the present invention. For example, it can be carried out by detecting the binding between the substance to be examined (hereinafter referred to as the test substance) and the protein by a known binding analysis method. Alternatively, in the identification method using cells expressing this protein, it can be carried out by measuring the cellular response of the cells induced when a test substance is brought into contact with the protein. The cellular response when a test substance is brought into contact with the protein changes compared to when the test substance is not brought into force (acceleration, generation, reduction or elimination).
- the test substance is lost, it can be determined that the test substance is a ligand or contains a ligand.
- Specific examples of the cellular response include changes in cell membrane potential or changes in intracellular calcium concentration. Measurement of cell membrane potential or intracellular calcium concentration can be carried out by a method known per se.
- the target ligand can also be obtained by measuring the interaction between the protein and the MAGUK family-related protein as an indicator of cell response. When the interaction between this protein and the MAGUK family-related protein in the cell when the test substance is brought into contact with the protein is changed (promoted or generated) compared to when the test substance is not brought into contact, the test substance is It can be determined to be ligand or contain a ligand. The interaction between this protein and the MAGUK family-related protein can be detected by a method known per se such as immunoblotting.
- test substance to be used for identifying the ligand examples include, for example, a cell in which expression of DNA used in the present invention is observed, or a sample in which the tissue strength is also prepared. Some can also target various compounds derived from natural products or synthesized.
- Such an identification method is useful for determining whether or not a sample contains a ligand, as well as in the process of purifying a sample force ligand that has been found to contain a ligand. However, it can be used effectively. For example, when a sample is fractionated and purified using gel filtration chromatography or the like, it can be determined whether or not the fraction contains a ligand.
- the compound obtained by the identification method according to the present invention is an inhibitor, antagonist, or the like of the function of the protein used in the present invention, for example, binding to a ligand, activation of intracellular signal transduction, induction of a cellular response, etc. It can be used as an accelerator or stabilizer. Further, it can be used as an expression inhibitor or expression promoter at the gene level for the protein used in the present invention.
- These compounds can be prepared as pharmaceuticals by further screening considering the balance between biological usefulness and toxicity. In addition, these compounds can be expected to have a preventive effect and a Z or therapeutic effect on various pathological symptoms caused by abnormal functions of the protein and the expression of Z or DNA encoding the protein.
- Protein, DNA, recombinant vector, transformant, antibody, regan used in the present invention is useful as an active ingredient of a medicament or pharmaceutical composition based on inhibiting, antagonizing or promoting the function and Z or expression of the present protein.
- the medicament or pharmaceutical composition according to the present invention is used as a Z- or therapeutic agent for the prevention of diseases caused by the function of the protein used in the present invention and the abnormal expression of Z or DNA encoding the protein. it can. It can also be used for prevention and Z or treatment of the disease.
- an effective amount of inhibiting the function of the protein and the expression of Z or the DNA may be used.
- An inhibitor can be administered to a subject together with a pharmaceutically acceptable carrier to inhibit the function of the protein, thereby improving abnormal symptoms.
- the expression of DNA encoding the endogenous protein may be inhibited using an expression block method.
- a fragment of this DNA can be used as an antisense oligonucleotide for gene therapy to inhibit the expression of the DNA encoding this protein.
- a DNA fragment used as an antisense oligonucleotide is useful even if it corresponds to an untranslated region that extends beyond the translated region of this DNA.
- a neurological disease such as depression is preferably mentioned.
- the expression of this protein is strongly observed in brain tissues, particularly in the cerebral cortex, hippocampus and amygdala, and is consistent with the expression distribution of CCK, which is a ligand for the functional membrane protein receptor that is the protein.
- CCK is known to be involved in physiological functions such as anxiety, analgesia, sedation, suppression of eating, memory, and learning.
- the mouse showed an antidepressant-like phenotype.
- the BAI2 gene is a splicing variant of DNA encoding this protein.
- the inventors consider that a splicing variant of DNA encoding this protein is involved in depression. For example, the inventors believe that depression is induced by an abnormality when the expression of DNA encoding the protein or a splicing variant of the DNA increases.
- an inhibitor of the function and Z or expression of the protein used in the present invention such as the present protein.
- the medicament or pharmaceutical composition according to the present invention can be used for the prevention and Z or treatment method of depression.
- the pharmaceutical or pharmaceutical composition comprises an effective amount of an inhibitor of the protein function and Z or expression, for example, an antagonist of a membrane protein receptor capable of the protein, as an active ingredient.
- Prevention and Z or therapeutic agent in other words, the present medicament or pharmaceutical composition may be a preventive and Z or therapeutic agent for depression comprising the effective amount of the antidepressant as an effective component.
- the protein As a disease caused by abnormal expression of the function of the protein used in the present invention and Z or DNA encoding the protein, the protein has a TSP-I domain in the amino acid sequence, so that angiogenesis is inhibited. And diseases associated with angiogenesis inhibition. Since the TSP-I domain has been reported to be a domain responsible for angiogenesis inhibition function, this protein is considered to have angiogenesis inhibition function. Therefore, this protein may be involved in diseases caused by angiogenesis inhibition and diseases associated with angiogenesis inhibition. In such diseases, it is preferable to inhibit the function and expression of this protein, since it can be treated by promoting angiogenesis. Examples of such diseases include cerebral contusion and cerebral infarction.
- the protein may be produced in cells in a subject using gene therapy.
- known methods can be used. For example, a replication-deficient retroviral vector incorporating the present DNA or RNA that is a transcription product of the DNA is prepared, and cells derived from the subject are treated in an ex vivo using the vector, and then the cells are targeted. Can also be introduced.
- the medicament according to the present invention may be a medicament comprising an effective amount of at least one of the protein, DNA, recombinant vector, transformant, antibody, ligand or compound as an active ingredient. However, it is usually preferred to produce a pharmaceutical composition using one or more pharmaceutical carriers.
- the amount of the active ingredient contained in the pharmaceutical preparation according to the present invention is appropriately selected from a wide range of forces. Usually about 0.0001 to 70% by weight, preferably about 0.0001 to 5% by weight. Is appropriate.
- Diluents and additives such as fillers, extenders, binders, moisturizers, disintegrants, surfactants, lubricants and the like that are usually used as pharmaceutical carriers depending on the form of use of the preparation. Examples of the dosage form can be given. These are appropriately selected and used depending on the administration form of the resulting preparation.
- water pharmaceutically acceptable organic solvent
- collagen polybulal alcohol, polybulurpyrrolidone, carboxybulu polymer, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, xanthan gum, gum arabic
- examples include zein, gelatin, agar, glycerin, propylene glycol, polyethylene glycol, serine serine, paraffin, stearyl alcohol, stearic acid, human serum albumin, mantol, sorbitol, and ratatose. These may be used alone or in combination of two or more according to the dosage form.
- the stabilizer examples include human serum albumin, ordinary L amino acids, saccharides, cellulose derivatives and the like, and these can be used alone or in combination with a surfactant or the like. In particular, according to this combination, the stability of the active ingredient may be further improved.
- the L-amino acid is not particularly limited, and may be any of glycine, cysteine, glutamic acid and the like.
- Sugars are not particularly limited, for example, monosaccharides such as glucose, mannose, galactose and fructose, sugar alcohols such as mannitol, inositol and xylitol, disaccharides such as sucrose, maltose and lactose, dextran, hydroxypropyl starch, chondroit Any of polysaccharides such as phosphoric acid and hyaluronic acid, and derivatives thereof may be used.
- cell The cellulose derivative is not particularly limited and may be any of methyl cellulose, ethyl cellulose, hydroxyethylenosulose, hydroxypropenoresenorelose, hydroxypropinoremethinoresenolose, sodium carboxymethylcellulose, and the like.
- both ionic and nonionic surfactants can be used. This includes, for example, polyoxyethylene glycol sorbitan alkyl ester, polyoxyethylene alkyl ether, sorbitan monoacyl ester, and fatty acid glyceride.
- boric acid As a buffering agent, boric acid, phosphoric acid, acetic acid, cuenic acid, ⁇ -aminocaproic acid, glutamic acid and ⁇ or a salt thereof (for example, an alkali such as sodium salt, potassium salt, calcium salt, magnesium salt, etc.) Examples thereof include metal salts and alkaline earth metal salts.
- isotonic agents include sodium chloride sodium, potassium salt potassium, saccharides, glycerin and the like.
- Examples of the chelating agent include sodium edetate, citrate and the like.
- the medicine and pharmaceutical composition according to the present invention can be used as a solution preparation, and after freezing, drying and storage, the medicine and the pharmaceutical composition can be used with water, saline, etc. at the time of use. It can also be used after it is dissolved in a buffer solution or the like and adjusted to an appropriate concentration.
- the dosage range of the pharmaceutical composition is not particularly limited, and the effectiveness of the ingredients contained, the mode of administration, the route of administration, the type of disease, the nature of the subject (weight, age, medical condition, and the use of other drugs) Inequality) and the decision of the doctor in charge.
- a suitable dose is, for example, in the range of about 0.01 ⁇ g to 100 mg, preferably about 0.1: L g to 1 mg, per kg of body weight of the subject.
- these doses can be varied using general routine experimentation for optimization well known in the art.
- the above dose can be administered once to several times a day, and may be administered intermittently at a rate of once every several days or weeks.
- the pharmaceutical composition When administering the pharmaceutical composition according to the present invention, the pharmaceutical composition may be used alone or in combination with other compounds or medicines necessary for treatment.
- the administration route can be selected from systemic administration or local administration! In this case, disease, symptom
- An appropriate administration route is selected according to the condition.
- parenteral routes include normal intravenous administration, intraarterial administration, subcutaneous, intradermal, intramuscular administration and the like. Alternatively, it can be administered by the oral route.
- transmucosal administration or transdermal administration can also be performed. When used for cancer diseases, it is preferable to administer directly to the tumor by injection or the like.
- various forms can be selected according to the purpose. Typical examples are solid dosage forms such as tablets, pills, powders, powders, fine granules, granules, capsules, aqueous solutions, ethanol solutions, suspensions, fat emulsions, ribosome formulations. And inclusion forms such as cyclodextrin, and liquid dosage forms such as syrup and elixir.
- these preparations are also oral, parenteral (instillation, injection), nasal, inhalation, vaginal, suppository, sublingual, eye drops, ear drops, ointments, They are classified into creams, transdermal absorbents, transmucosal absorbents, etc., and can be prepared, molded and prepared according to ordinary methods.
- the pharmaceutical composition according to the present invention is used as a gene therapy agent, in general, it is preferably prepared as an injection, an infusion, or a ribosome preparation.
- the gene therapy agent is prepared in a form containing cells into which the gene has been introduced, the cells are formulated in phosphate buffered saline (PH7.4), Ringer's solution, or an injection for intracellular composition. It can also be prepared in form. It can also be prepared in such a form that it can be administered together with a substance that improves gene transfer efficiency such as protamine.
- the pharmaceutical composition can be administered once or divided into several times a day, and can be intermittently administered at intervals of 1 to several weeks. The administration can be carried out according to a method used in general gene therapy.
- the protein, DNA, recombinant vector, transformant, antibody or compound used in the present invention can itself be used as a disease diagnostic means such as a diagnostic marker or a diagnostic reagent.
- Specific detection of the presence or absence or expression of an abnormality in an individual or various tissues of a gene containing DNA used in the present invention can be carried out according to the present invention, for example, by analyzing the partial or entire base sequence of the present DNA. It can be implemented by using it. By detecting this DNA, diagnosis of the susceptibility, onset, and Z or prognosis of diseases caused by the gene is performed. it can.
- the disease caused by the gene means a disease caused by a quantitative abnormality and Z or functional abnormality of the gene. Examples of diseases caused by this gene include neurological diseases such as depression.
- Diagnosis of a disease by detecting a gene is performed by, for example, detecting the presence of a nucleic acid corresponding to the gene, determining the abundance, and identifying Z or a variation thereof in a test sample. Can be implemented. In comparison with a normal control sample, it is possible to detect a change in the presence of nucleic acid corresponding to the target gene and its quantitative change. Further, in comparison with the normal genotype, deletions and insertions can be detected by measuring, for example, the size change of the amplified product obtained by amplifying the nucleic acid corresponding to the target gene by a known technique. Point mutations can be identified by hybridizing amplified DNA with, for example, labeled DNA used in the present invention. The above diagnosis can be carried out by detecting such changes and mutations.
- a qualitative or quantitative measurement method of a target gene in a test sample or a qualitative or quantitative measurement method of a mutation in a specific region of the gene can also be carried out by the present invention.
- the test sample is not particularly limited as long as it contains the nucleic acid of the target gene and Z or its mutant gene.
- biological samples such as cells, blood, urine, saliva, spinal fluid, tissue biopsy or autopsy material
- Biological samples derived from living organisms can be exemplified.
- a nucleic acid sample can be prepared by extracting a nucleic acid from a biological sample.
- the nucleic acid may be used directly for detection of genomic DNA or may be amplified enzymatically by using PCR or other amplification methods prior to analysis.
- RNA or cDNA may be used as well.
- Nucleic acid samples may also be prepared by various methods that facilitate the detection of the target sequence, such as denaturation, digestion with restriction enzymes, electrophoresis or dot blotting.
- a known gene detection method can be used. For example, plaque hybridization, colony hybridization, Southern blot, Northern blot, Nucleic Acid Sequence-Based Amplification (NASBA), Or RT—PCR and the like. In addition, measurement at the cell level using in situ RT-PCR, in situ hybridization or the like can also be used. Used to detect target genes The methods that can be used are not limited to the above methods, and any gene detection method known per se can be used.
- a DNA fragment used in the present invention for identifying the target gene or its mutant gene and performing Z or its amplification, and having a property as a probe, or Those having properties as a primer are useful.
- a DNA fragment having the properties as a probe means a DNA fragment that can be specifically hybridized only to the target DNA and also has an arrangement ability peculiar to the DNA.
- What has the property as a primer means the thing which consists of an arrangement
- a primer or probe having a sequence of a predetermined length including a portion having a mutation in the gene is prepared and used.
- the probe or primer generally has a base sequence length of about 5 to 50 nucleotides, preferably about 10 to 35 nucleotides, and more preferably about 15 to 30 nucleotides.
- the probe is usually a labeled probe, but may be unlabeled or may be detected by specific binding with a directly or indirectly labeled ligand. Numerous methods are known for labeling probes and ligands, and examples include methods using nick translation, random priming, or kinase treatment. Suitable labeling substances include radioisotopes, piotin, fluorescent dyes, chemiluminescent substances, enzymes, antibodies and the like.
- PCR is the point of sensitivity. PCR is not particularly limited as long as it is a method using a DNA fragment capable of specifically amplifying a target gene as a primer, and can be exemplified by conventionally known methods such as RT-PCR. Variations can be applied.
- PCR can also quantify the DNA of the target gene and Z or its mutant gene.
- Such analysis methods are known as competitive quantification methods such as the Multi-channel Simplex Stimulated Annealing (MSSA) method, or mutation detection methods that utilize changes in mobility associated with changes in higher-order structure of single-stranded DNA.
- MSSA Multi-channel Simplex Stimulated Annealing
- P CR—SSCP method can be exemplified.
- Diagnosis of a disease by detecting a protein can be carried out, for example, by detecting the presence of the protein, determining the amount of the protein, and detecting Z or a mutation thereof in a test sample. That is, this protein and Z or a mutant thereof are measured quantitatively or qualitatively. A change in the presence of the target protein and its quantitative change can be detected in comparison with a normal control sample. In comparison with a normal protein, for example, the mutation can be detected by determining the amino acid sequence. The above diagnosis can be carried out by detecting such changes and mutations.
- the test sample is not particularly limited as long as it contains the target protein and Z or a variant thereof, and examples thereof include biological samples derived from living organisms such as blood, serum, urine, and biopsy tissue.
- the protein used in the present invention and the measurement of the protein having a mutation are determined by measuring the present protein, for example, the protein represented by the amino acid sequence set forth in SEQ ID NO: 2 in the sequence listing, It can be carried out by using an amino acid sequence in which two or more amino acids have been deleted, substituted, inserted or added, a fragment thereof, or an antibody against the protein or a fragment thereof.
- Quantitative or qualitative measurement of a protein can be performed using a protein detection method or a quantification method according to a conventional technique in this field.
- the mutant protein can be detected by analyzing the amino acid sequence of the target protein.
- the antibody polyclonal or monoclonal antibody
- the antibody can be used to detect the difference in the sequence of the target protein or the presence or absence of the target protein.
- a qualitative or quantitative measurement method of a protein used in the present invention in a test sample, or a qualitative or quantitative measurement method of a mutation in a specific region of the protein can be carried out by the present invention.
- the detection can be carried out by subjecting a test sample to immunoprecipitation using a specific antibody against the target protein and analyzing the target protein by Western blotting or immunoblotting.
- antibodies against the target protein can be The protein of interest can be detected in paraffin or frozen tissue sections using biological techniques.
- Preferred methods for detecting the target protein or its variants include specific examples of enzyme immunoassay (ELISA) and radioimmunoassay (including sandwich methods using monoclonal antibodies and Z or polyclonal antibodies). RIA), immunoradiation assay (IRMA), and immunoenzyme method (IEMA). In addition, a radio-immune competition can be used for IJ.
- enzyme immunoassay ELISA
- radioimmunoassay including sandwich methods using monoclonal antibodies and Z or polyclonal antibodies.
- RIA immunoradiation assay
- IEMA immunoenzyme method
- a radio-immune competition can be used for IJ.
- any of the proteins, DNAs, recombinant vectors, transformants, and antibodies used in the present invention can be used alone as a reagent.
- the method for identifying a compound according to the present invention or the invention can be used as a reagent for measuring protein and Z or DNA.
- This reagent is useful for elucidation of cell signal transduction pathways involving this protein or DNA, and for basic research on diseases caused by abnormalities of the protein and Z or DNA.
- the reagent kit according to the present invention includes DNA represented by at least one of the base sequences described in SEQ ID NOs: 1, 15, and 17 in the sequence listing, and the DNA
- An example is a reagent kit containing at least one of a recombinant vector, a transformant introduced with the recombinant vector, a protein encoded by the DNA, and an antibody that recognizes the protein. it can.
- DNA represented by any one base sequence a recombinant vector containing the DNA, and the recombinant vector A transformant into which at least one of the protein represented by the amino acid sequence of any one of the amino acid sequences set forth in SEQ ID NOs: 2, 16, and 18 and an antibody that recognizes the protein
- a reagent kit containing one is a reagent kit containing one.
- reagents When these are reagents, they may contain buffers, salts, stabilizers, and substances such as Z or preservatives. It should be noted that in formulating, any known formulating means corresponding to each property may be introduced.
- a reagent kit comprising at least one of the protein, DNA, recombinant vector, transformant, and antibody used in the present invention is provided by the present invention.
- these are reagent kits they are required for carrying out measurements such as labeling substances for detecting the protein and DNA, labeling detection agents, reaction diluents, standard antibodies, buffers, detergents, and reaction stop solutions. Substances may be included.
- the labeling substance include the above-described labeling protein and chemically modified substance, but the labeling substance may be added to the present protein or DNA in advance.
- the reagent kit according to the present invention can be used in the above identification method and measurement method. Furthermore, the present invention can be used as a test agent and a test kit in a test method using the measurement method. Moreover, it can also be used as a diagnostic agent and a diagnostic kit for a diagnostic method using the above-described measurement method.
- a cDNA library is constructed in the usual way using polyA + RNA (manufactured by Clontech: Catalog Nos. 6516-1, 6525-1, and 6578-1) from human brain, fetal brain, and brain hippocampus.
- the cDNA fragment was isolated by dbEST analysis and the base sequence of the cDNA clone was determined. Specifically, derived from the above-mentioned human brain prepared according to the method of Ohara et al. (Ohara, O. et al., “DNA Research”, 1997, IV, p. 53-59).
- the ORF was predicted by a general-purpose analysis method using a computer program V, and a cDNA clone having a 7-transmembrane domain was obtained in this region. .
- the identified cDNA clone, ph01207 has a DNA sequence (SEQ ID NO: 1) with a total length of 4557 bp, including an ORF that has a 1518 amino acid residue strength and has a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus). ).
- SEQ ID NO: 1 The identified cDNA clone, ph01207, has a DNA sequence (SEQ ID NO: 1) with a total length of 4557 bp, including an ORF that has a 1518 amino acid residue strength and has a portion predicted to be a signal sequence (20 amino acid residues from the N-terminus).
- SEQ ID NO: 2 GenBank accession number AB005298
- the region coding for 55 amino acid residues in the N-terminal region is deleted, and one amino acid residue (the amino acid sequence described in SEQ ID NO: 2) is also present in the C-terminal region. It was considered that the splicing variant was inserted at the 1406th ly
- the protein encoded by ph01207 was found to have three TSP-I domains as well as a GPS domain and a seven-transmembrane domain as structural features.
- the protein encoded by hBAI2 is thought to have a GPS domain and a seven-transmembrane domain in addition to the four TSP-I domains.
- the protein encoded by ph01207 it was revealed that 55 amino acid residues corresponding to the region containing one TSP-I domain on the N-terminal region side of hBAI2 were deleted.
- the protein encoded by ph01207 was expressed as an N-terminal epitope-tag fusion protein.
- an expression vector containing the phO 1207 gene was constructed.
- the DNA encoding the amino acid sequence excluding the signal sequence and the predicted portion (20 amino acid residues from the N-terminus) was cloned into pDONR 201 by PCR and restriction enzyme treatment.
- the ph01207 entry vector was constructed.
- PCR was performed using an oligonucleotide represented by the nucleotide sequence described in each of SEQ ID NO: 4 to L1 in the sequence listing as a primer and Pfu turbo DNA polymerase (Stratagene) as a polymerase.
- p3 X FLAG- CMV9- attR uses p3 X FLAG-CMV9 (Sigma) as a gateway vector conversion system (GA TEWAY Vector Conversion System (manufactured by Invitrogen) is a vector that is compatible with the GATEWAY system.
- G TEWAY Vector Conversion System manufactured by Invitrogen
- T8HA—attRZp CINeo is the literature information (Koller, KJ et al., “Analytical Biochemistry”, 1997, No. 250, p. 51—60).
- FITC fluorescein isothiocyanate
- HA-ph01207 # 10-6 was assigned the accession number FERM BP-10101 and the National Institute of Advanced Industrial Science and Technology (AIST) Was deposited on August 19, 2004. The survival of this cell line has been confirmed by a test conducted on September 22, 2004 at the Deposit Center.
- the HA-ph01207 # 10-6 cell line has a signal sequence (from the N-terminus of the amino acid sequence described in SEQ ID NO: 2) of the DNA open reading frame (ORF) represented by the base sequence described in SEQ ID NO: 1.
- Functional analysis of the ph01207 gene product was performed by measuring the cellular response when a ligand was added to Xenopus oocytes expressing ph01207. Egg when measuring the cellular response, the control oocytes (those not introduced genes) and genes with (P h01207 c DNA clone) oocyte that expressed one by six each, were added ligand The measurement was performed by measuring changes in membrane potential of the mother cells. As a ligand, a culture supernatant of a HeLa cell line that was found to express ph01207 was used.
- the culture supernatant should be 1.2 x 10 6 HeLa cell line cultured in DMEM containing 10% fetal bovine serum for 2 days, and the culture supernatant should be collected and filtered (0.45 m). It was prepared by. Two types of culture supernatants prepared in the same lot were used as ligands (hereinafter referred to as ligand samples 1 and 2).
- Ligand sample 1 or 2 was added to oocytes expressing the phO 1207 gene and control oocytes, and changes in membrane potential were measured. The evaluation is based on the change in current amount and the waveform showing the change in current amount. If there was a waveform of a unique pattern, it was determined that there was a response to ligand stimulation
- the GPCR-specific pattern refers to the waveform 1 pattern shown in FIG.
- the patterns such as waveforms 2 to 4 shown in Fig. 3 are waveform patterns generated by the influence of some components such as solvents or artificial factors such as high concentrations of ligands, and were determined not to be responses to ligand stimulation. In addition, when patterns such as waveforms 5 and 6 were observed, it was determined that there was no response to ligand stimulation.
- the phOl 207 gene product Since the ph01207 gene expression produced a cellular response due to ligand stimulation, the phOl 207 gene product has a function of activating the intracellular signal transduction pathway in response to the ligand. Think of it as a GPCR.
- the protein interaction analysis of the ph01207 gene product was examined using the yeast two-hybrid system.
- the N-terminal region (4 sites) and C-terminal region (2 sites) of the ph01207 gene product, and the N-terminal region of the hBAI2 gene product were selected from the report on the expression distribution of hBAI2 (non-patent document 1), in which a bait was set for the C-terminal region (region with one amino acid residue inserted in ph01207) Screening was performed against cDNA libraries (derived from brain, hippocampus, breast and prostate cancer, heart and skeletal muscle).
- MAGUK family-related proteins are present in the cytoplasm, such as receptors and ion channels present in the cell membrane. It is involved in signal transduction of these membrane proteins by binding to other membrane proteins. Therefore, the ph01207 gene product and the hBAI2 gene product are functional membrane protein receptors involved in intracellular signal transduction via MAGUK family-related proteins.
- HA-ph01207 is a strain obtained by cell-cloning one of the cell lines stably expressing the protein encoded by ph01207 as an HA-tag fusion protein. # 10—6 cell lines were used.
- CCK-8NS is a CCK Ota peptide represented by the same amino acid sequence as CCK-8S (SEQ ID NO: 14). The 7th tyrosine residue from the C-terminal is not sulfated.
- CCK 4 is a tetrapeptide consisting of amino acid residues from the C-terminal to the fourth position of CCK-8S (SEQ ID NO: 14).
- DMEMZF12 (Gibeo) containing 10% fetal calf serum (Moregate) was used. The next day, remove 50 / zL of the medium from each well, add 50 L of loading buffer to each well, and allow to react for 1.5 hours at room temperature. The fluorescent dye contained therein was taken up into the cells.
- the loading buffer is composed of component A of FLIPR Calcium 3 Assembly Kit (manufactured by Molecular Device), 9.9 mL of component B with 0.1 mL of 500 mM probenecid (probenecid Sigma). It was prepared by dissolving in a prepared solution.
- CCK-8S (SEQ ID NO: 14) was prepared by dissolving 0.52 mg with 4.5 mL of 1% NaHCO (manufactured by Wako) and adding 0. ImM
- CCK-8NS was prepared by dissolving 0.53 mg in 0.50 mL of dimethyl sulfoxide (DMSO, Sigma) and then adding 4. 50 mL of double-distilled water H 2 O. 0. ImM
- CCK-4 SEQ ID NO: 14
- CCK-8NS SEQ ID NO: 14
- CCK-8NS CCK-4 are each diluted with phosphate buffered saline (PBS) to give a 5nM solution, each containing 25 ⁇ L (final concentration InM).
- PBS phosphate buffered saline
- A23187 manufactured by Calbiochem was used at a final concentration of 10 M as a positive control that caused an increase in intracellular Ca 2+ concentration.
- the CHO-K1 cell line used as the host was used for the production of the HA-ph01207 # 106 cell line. Since the ph01207 expression vector is not transfected into the CHO K1 cell line, the phO1207 gene product is expressed.
- the CHO-K1 cell line did not show an increase in intracellular Ca 2+ concentration when stimulated with CCK 8S (SEQ ID NO: 14), CCK 8NS, or CCK-4 (Fig. 4). — A, Figure 4-B and Figure 4-C). However, A23187 increased the intracellular Ca 2+ concentration of CHO-K1 cells (Fig. 4D). [0323] From these results, it was revealed that HA-ph01207 # 10-6 cell line strength CCK-8S (SEQ ID NO: 14) specifically responded.
- CCK-8S (SEQ ID NO: 14) is considered to be a ligand for the phOl 207 gene product.
- CCK-8S SEQ ID NO: 14
- CCK-8S SEQ ID NO: 14
- CCK-8S SEQ ID NO: 14
- CCK-8 is actually a protein encoded by ph01207 in vivo. It is thought that the cell response is induced through the.
- CCK 8S SEQ ID NO: 14
- CCK 8S is considered to be one of the in vivo ligands of ph01207 predicted to be GPCR.
- a splicing variant of the ph01207 gene was obtained by RT-PCR cloning.
- the splicing noreant of the ph01207 gene was obtained as follows. First, a cDNA library was constructed by a conventional method using polyA (+) RNA (manufactured by Clontech) derived from human brain as a starting material, and a cDNA fragment was isolated by dbEST analysis to determine the base sequence of the cDNA clone. Specifically, 10 L of anti-i yarn containing 0.1 g of polyA (+) RNA ⁇ Superscript first-strand synthesis system for RT-P and RT-PCR using R (Invitrogen), A cDNA library was constructed.
- PCR was carried out using this cDNA as a saddle and using an oligonucleotide having the nucleotide sequence of SEQ ID NO: 23 and an oligonucleotide having the nucleotide sequence of SEQ ID NO: 24 as primers.
- PCR using these primers revealed that hBAI2 (SEQ ID NO: 22) had aspartic acid (D) at the 44th position as well as DNA in the region encoding the amino acid sequence up to the 475th cysteine (C), and hBAI2 In the splicing variant of (SEQ ID NO: 22), DNA corresponding to the region is amplified (see FIG. 1-C).
- cDNA clones that were considered to be splicing variants of the ph01207 gene were obtained. These cDNA clones are referred to as 7tmHR gene, hkO 1941 gene and variant 3 gene. All of these splicing variants differ in the number of TSP-I domain repeats in the N-terminal extracellular region (Fig. 1-B). Of these splicing variants, the 7tmHR gene encodes the longest protein.
- the 7tmHR gene consists of a 4719 bp nucleotide sequence containing an ORF encoding 1573 amino acid residues (SEQ ID NO: 20) having a signal sequence and a predicted portion (20 amino acid residues from the N-terminus) (SEQ ID NO: 20). 19).
- the 7tmHR gene is registered with GenBank as accession number: AB 065648.
- the protein encoded by this gene has seven transmembrane domains, four TSP-I domains and one GPS domain (see Figure 1-B).
- the protein has the same amino acid sequence as hBAI2 except that one amino acid residue is inserted in the C-terminal region compared to the sequence of hBAI2 (GenBank accession number AB005298).
- the insertion of the 1 amino acid residue is observed between the 1460th glutamic acid (E) and the 1461st Norin (V) of the amino acid sequence of hBAI2, and the inserted amino acid residue is lysine. .
- the inserted lysine corresponds to position 1461 in the amino acid sequence of the protein (SEQ ID NO: 20) encoded by the 7tmHR gene. Based on sequence homology and structural similarity, the 7tmHR gene and the protein encoded by the gene were considered to be splice variants of the hBAI2 gene.
- the hk01941 gene is a novel gene, 4389 bp base containing ORF encoding 1463 amino acid residues (SEQ ID NO: 16) having a signal sequence and a predicted portion (20 amino acid residues from the N-terminus). There will also be alignment power (SEQ ID NO: 15).
- the protein encoded by this DNA has seven transmembrane domains, two TSP-I domains and one GPS domain (see Figure 1-B).
- the amino acid sequence of the protein encoded by this DNA lacks 110 amino acid residues including two N-terminal TSP-I domains compared to the protein encoded by the 7tmHR gene (SEQ ID NO: 20). It is the same except that it is lost. Deletion 110 ru In the amino acid sequence of the protein encoded by the 7tmHR gene (SEQ ID NO: 20), the mino acid residue corresponds to the 296th glycine (G) force of the 405th proline (P).
- Variant 3 gene is a novel gene, 4554 bp nucleotide sequence containing ORF encoding 1518 amino acid residues (SEQ ID NO: 18) having a signal sequence and a predicted portion (20 amino acid residues from the N-terminus) It also has power (SEQ ID NO: 17).
- the protein encoded by this DNA has seven transmembrane domains, three TSP-I domains and one GPS domain (see Figure 1-B).
- the amino acid sequence of the protein encoded by DNA lacks 55 amino acid residues including the second TSP-I domain from the N-terminal side. It is the same except for losing.
- the 55 amino acid residues that are deleted are the amino acid sequence of the protein encoded by the 7tmHR gene (SEQ ID NO: 20), and the 351st palin (V) force is also applied to the 405th proline (P).
- the amino acid sequence of the protein encoded by the ph01207 gene is compared to the amino acid sequence of the protein encoded by the 7tmHR gene (SEQ ID NO: 20). It is the same except that 55 amino acid residues are deleted. The deleted 55 amino acid residues are included in the amino acid sequence of the protein encoded by the 7tmHR gene (SEQ ID NO: 20)! /, And the 296th glycine (G) to the 350th proline (P ).
- a stable expression strain of the splicing noreant of the ph01207 gene was constructed, and it was examined whether a cell response by CCK-8S was induced in the stable expression strain.
- the three types of splicing variants obtained in Example 6, the 7tmHR gene, the hk01941 gene, and the variant 3 gene were used as the splicing nootropics.
- each full-length cDNA clone was recombined with each full-length cDNA clone using pc DNA3.1 (+) (manufactured by Invitrogen), which is an expression vector for animal cells. Asp718I and Notl Built by doing The resulting expression vectors are referred to as 7tm HR / pcDNA3.1, hk01941 / pcDNA3.1 and variant3 / pcDNA3.1. To do.
- the 7tmHR stable expression strain and hk01941 stable expression strain transfect the 7tmHR expression vector (7tm HR / pcDNA3.1) and hk01941 expression vector (hk0194lZpcDNA3.1), respectively, into the CHO-K1 cell line.
- the expression vector was mixed with Lipofectamine 2000 (Lipofectamine 2000, sometimes abbreviated as LF2000, manufactured by Invitrogen) (4 g DNA / 250 ⁇ L DMEM / F 12 medium + 10 / z L LF2000 / 250 ⁇ L DMEMZF12 medium) and CHO-K1 strain (2 mL medium Zwell) cultured on 6-well plates were added for transfection.
- Lipofectamine 2000 Lipofectamine 2000, sometimes abbreviated as LF2000, manufactured by Invitrogen
- cells are collected, seeded on a 96-well plate at a cell density of 1 cell Zwell, and cultured in a selective medium containing G418 (400 ⁇ g / mL) (DMEM / F12 medium containing 10% FCS).
- DMEM / F12 medium containing 10% FCS a selective medium containing G418 (400 ⁇ g / mL)
- Expression cell lines were selected.
- the selected expression cell lines were subjected to FCM analysis and Western blotting analysis using anti-hBAI2 antibody to confirm the expression of the introduced gene.
- Cells are seeded in 96 well plates (plates with black walls and transparent bottoms) in a 3 x lo lOO ⁇ L medium Zwell, and are placed in a 5% CO incubator at 37 ° C.
- Koji was cultured. The next day, remove 50 ⁇ L of the medium from each well, add 50 ⁇ L of loading buffer to each well, react at room temperature for 1 hour, and contain in the loading buffer. A fluorescent dye was incorporated into the cells.
- the loading buffer was prepared in the same manner as described in Example 5. After the reaction, flexstay Using Chillon (FLEXstation, manufactured by Molecular Device), the time-dependent change in fluorescence intensity at the time of adding CCK-8S was measured for each well. CCK-8S was used at a final concentration of ⁇ -1 M. A23187 was used at a final concentration of 20 ⁇ as a positive control for Atsey.
- Fig. 5-A shows changes in intracellular calcium (Ca 2+ ) concentration when a physiologically concentrated (1 nM) CCK-8S was added to a representative clone of 7tmHR stable expression strain and hk01941 stable expression strain.
- Figure 6-A Similar responses were observed in both the expression cell line and the host cell for A23187 (20 M) used as a positive control (Fig. 5-B and Fig. 6-: B).
- Koji was cultured. The next day, remove 50 ⁇ L of the medium from each well, add 50 ⁇ L of loading buffer to each well, react at room temperature for 1 hour, and contain in the loading buffer. A fluorescent dye was incorporated into the cells.
- the loading buffer was prepared in the same manner as described in Example 5. After the reaction, the time-dependent change of the fluorescence intensity at the time of adding CCK-8S was measured for 40 seconds using a flex station (FLEXstation, manufactured by Molecular Device). CCK 8S was used at a final concentration of ⁇ — 1 M. As a positive control for Atsey, ⁇ 23187 was used at a final concentration of 20 ⁇ .
- FIG. 7-A shows changes in intracellular calcium (Ca 2+ ) concentration when a physiological clone (InM) of CCK-8S is added to a representative clone of a variant 3 stable expression strain. The same response was observed in both the expression cell line and the host cell for A23187 (20 ⁇ ) used for the positive control (Fig. 7- 7).
- CCK 8S supplementation observed changes in intracellular calcium (Ca 2+ ) concentration that was not observed in host cells.
- the product is thought to mediate the cellular response elicited by CCK 8S. That is, all of the variant 3 gene products are expressed on the surface of the cell membrane, and by the action of extracellular CCK 8S, the intracellular signal transduction pathway is activated and the intracellular calcium (Ca 2+ ) concentration is increased. It is thought that the rise and the cellular response were triggered.
- Tissue expression of the phO 1207 gene was analyzed using LifeSpan DrugTarget Database TM (LifeSp an Biosciences) and BioExpress Database (Gene Logic).
- Tissue immunostaining data obtained with three types of rabbit anti-human BAI2 polyclonal antibodies (LS—A981, A982, A984; manufactured by Life Span) by analysis by searching the Lifespan DrugTarget Database (LifeSpan Biosciences) From the amygdala, hippocampus, medulla, thalamus, substantia nigra, cerebral cortex-euron and astrocytes, some cells of the anterior pituitary gland, and herring of the posterior pituitary gland. It became clear that Fig. 8-A and Fig.
- FIG. 8-B show tissue immunostaining data with proto plasmic astrocytes of amygdala and LS-A981 of amygdala-euron and glia, respectively.
- Fig. 8-C and Fig. 8-D show the tissue immunostaining data by LS-A981 of the hippocampal CA2 region -Euron and CA1 region -Euron, respectively.
- the ph01207 (hBAI2) gene was found to be strongly expressed in brain tissues, particularly in the cerebral cortex (cerebral temporal pole, motor cortex, etc.), hippocampus, and amygdala (Table 3). . This gene was almost unrecognizable in the digestive tract, such as the spleen, small intestine, stomach, and gallbladder.
- CCK A receptor (indicated as CCK AR in the table) is hardly expressed in brain tissue, and is confirmed to be expressed in the digestive tract such as spleen, stomach and gallbladder. (Table 3). It was also confirmed that CCK-B receptor (shown as CCK-BR in the table) is highly expressed in spleen and small intestine and is also expressed in brain tissues such as cerebral cortex, hippocampus and amygdala. (Table 3). The expression level of the ph01207 (hBAI2) gene in the brain tissue was higher than that of the CCK B receptor.
- BAI2 knockout mice were produced by gene disruption by homologous recombination. Specifically, the gene disruption by homologous recombination is based on the 976th aspartic acid (D) from 876th position of mouse BAI2 in the nucleotide sequence of mouse BAI2 gene (coding 1560 amino acid residues).
- a targeting vector targeting the leucine (L) encoding region (876D-917L region) was prepared, and the targeting vector was introduced into ES cells derived from 129Zo laHsd mice.
- the targeting vector includes the LacZ-Neo gene cassette, and the 5'arm of the cassette contains a genome sequence 0.8 kb upstream of the intron upstream of the 876 D-917L region of the mouse BAI2 gene.
- the 3 rule (3'arm) contains a genomic sequence 1.2 kb downstream from the intron downstream of the 876D-917L region of the same gene.
- the tail suspension test is a test method that measures the resting time until the mouse begins to move with the tail of the mouse fixed and upside down, and is one of the test methods for examining the phenotype of depression. This is a commonly used technique.
- Tail suspension test the evaluation of antidepressants, have been used as a test system to investigate the relevance of the depression (ester (Stem L.) et al., "Psycho Pharma Koroji one (p syc hopharmacology (Berl)) 1985, 85, 3, p. 367-3 70; Crowley JJ, et al., “Pharmacological Biochemical Behavior J, 2004, 78, 2”. 269-274; Nielsen DM et al., “European Journal of Pharmacology”, 2004, No. 499, 1-2, p. 135-146) .
- the tail suspension test was performed using 10 BAI2 knockout mice. As a control, a tail suspension test was similarly performed using 16 wild-type mice. [0359] BAI2 knockout mice had significantly reduced inactivity time compared to wild-type mice in the tail suspension test ( Figure 10). The results were expressed as mean standard error of immobility time of each mouse in the BAI2 knockout mouse group and the wild type mouse group. Significant differences were observed after statistical treatment using the T test.
- BAI2 knockout mice show an antidepressant-like phenotype, the BAI2 gene is thought to be associated with depression.
- a compound that inhibits the response of the ph01207 gene product to the ligand was identified by a system for measuring changes in intracellular calcium concentration using a ph01207-expressing cell line.
- a ph01207-expressing cell line was constructed as follows. First, the recombination by Asp718I (Boehringe r Co.) and NotI (TAKARA Co.) with the Example 1 P h0120 7 cDNA clones and pcDNA3. 1 identified in (Invitrogen Corporation), Do include Epitoputagu V, phO 1207 expression vector was constructed. The phO 1207 expression vector was transfected into CH O—Kl strain as a host cell using lipofectamine 2000 (manufactured by Invitrogen), and a stable expression strain was selected using a selective medium containing G418. Detection of transgene expression in the cells was performed by FCM analysis using an anti-phO1207 antibody.
- CCK 8S (Peptide Institute, Inc.) was used as the ligand.
- CCK-8S (SEQ ID NO: 14) was prepared by dissolving 0.52 mg with 4.5 mL of 1% NaHCO (manufactured by Wako) and adding 0. ImM concentration.
- a liquid was prepared.
- a compound library Soft Focus GPC Targeted Directed Library (manufactured by SoftFocus GPCR Targe-Directed Library, BioFocus) was used. In all cases, the compound was used by diluting a 2 mg / mL DMSO solution 25-fold with PBS to a concentration of 80 gZmL.
- the compound was specifically identified as follows. ph01207 # 3F8—17 strains were seeded in 96 well plates (black wall and transparent bottom) in 3 ⁇ 10 V 100 ⁇ L medium Zwell and at 37 ° C in the presence of 5% CO In culture. The medium is
- 6 X loading buffer is prepared by dissolving component A of FLIPR Calcium 3 Assay Kit (manufactured by FLIPR Calcium 3 Assay Kit ⁇ Molecular Device) with component B, and then adding probenecid (probenecid, Sigma) to a final concentration of 15 mM. In addition, it prepared so that it might become.
- CCK-8S manufactured by Peptide Institute
- a compound was added, and the change in fluorescence intensity with time was measured for 80 seconds for each well.
- the same measurement was performed using a buffer instead of the compound.
- the force or buffer was added to add the compound to a final concentration of 10 gZmL, and CCK-8S was added to a final concentration of C ⁇ 35 seconds after the addition of the compound or buffer.
- the measurement of the change in fluorescence intensity with time was performed using a flex station (FLEXstation, manufactured by Molecular Device).
- Compound B and Compound C are both ph0120 7 # 3F8—Inhibited the response of 17 strains ( Figure 11-B and Figure 11-C). This suggests that both Compound B and Compound C act as antagonists for the interaction between CCK-8S and ph01207.
- an antagonist that inhibits the response of ph01207 to its ligand for example, CCK-8S
- CCK-8S an antagonist that inhibits the response of ph01207 to its ligand
- a protein that acts as a functional membrane protein receptor having a seven-transmembrane domain, which is considered to be a GPCR, and a DNA encoding the protein.
- This protein is expressed on the cell membrane when expressed in cells, activates intracellular signal transduction by ligand stimulation, and causes a cellular response.
- the present invention it is possible to elucidate and regulate information transmission pathways and cell functions involving this protein.
- the present invention also makes it possible to prevent diseases caused by abnormalities of the protein and Z or DNA, such as depression, and to perform Z or treatment.
- the present invention is a useful tool that contributes widely to the field of basic science and drug development.
- SEQ ID NO: 1 DNA encoding a novel functional membrane protein receptor.
- SEQ ID NO: 2 protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 1.
- SEQ ID NO: 2 (408): (461) TSP—I domain.
- SEQ ID NO: 2 (870): (890) transmembrane domain.
- SEQ ID NO: 2 (1114): (1134) transmembrane domain.
- SEQ ID NO: 3 peptide represented by the amino acid sequence of SEQ ID NO: 2, hBAIl, and h
- SEQ ID NO 4 Oligonucleotide designed for primer.
- SEQ ID NO: 5 oligonucleotide designed for primer.
- SEQ ID NO: 6 oligonucleotide designed for primer.
- SEQ ID NO: 7 oligonucleotide designed for primer.
- SEQ ID NO: 8 oligonucleotide designed for primer.
- SEQ ID NO: 9 oligonucleotide designed for primer.
- SEQ ID NO: 10 oligonucleotide designed for primer.
- SEQ ID NO: 11 oligonucleotide designed for primer.
- SEQ ID NO: 12 synthetic oligonucleotide.
- SEQ ID NO: 13 synthetic oligonucleotide.
- SEQ ID NO: 15 DNA splicing variant set forth in SEQ ID NO: 1.
- SEQ ID NO: 16 protein encoded by the DNA represented by the base sequence set forth in SEQ ID NO: 15.
- SEQ ID NO: 16 1032 (1052) transmembrane domain.
- SEQ ID NO: 16 1059 (1079) transmembrane domain.
- SEQ ID NO: 17 A splicing variant of DNA described in SEQ ID NO: 1.
- SEQ ID NO: 18 A protein encoded by the DNA represented by the base sequence set forth in SEQ ID NO: 17.
- SEQ ID NO: 18 (352): (405) TSP—I domain.
- SEQ ID NO: 18 (408): (461) TSP—I domain.
- SEQ ID NO: 18 (870): (890) transmembrane domain.
- SEQ ID NO: 18 (899): (919) Transmembrane domain.
- SEQ ID NO: 18 (1114): (1134) transmembrane domain.
- SEQ ID NO: 19 A splicing variant of DNA set forth in SEQ ID NO: 1.
- SEQ ID NO: 20 A protein encoded by the DNA represented by the nucleotide sequence set forth in SEQ ID NO: 19.
- SEQ ID NO: 20 (352): (405) TSP—I domain.
- SEQ ID NO: 20 (407): (460) TSP—I domain.
- SEQ ID NO: 20 (983): (1003) Transmembrane domain.
- SEQ ID NO: 20 (1142): (1162) The transmembrane domain.
- SEQ ID NO: 20 (1169): (1189) the transmembrane domain.
- SEQ ID NO: 21 DNA encoding hBAI2, the DNA splice described in SEQ ID NO: 1 A single variant.
- SEQ ID NO: 22 protein encoded by the DNA represented by the base sequence set forth in SEQ ID NO: 21
- SEQ ID NO: 22 (352): (405) TSP—I domain.
- SEQ ID NO: 22 (407): (460) TSP—I domain.
- SEQ ID NO: 22 (983): (1003) Transmembrane domain.
- SEQ ID NO: 22 (1142): (1162) transmembrane domain.
- SEQ ID NO: 22 (1169): (1189) transmembrane domain.
- SEQ ID NO: 23 oligonucleotide designed for primer use.
- SEQ ID NO: 24 oligonucleotide designed for the primer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06745969A EP1884568A4 (en) | 2005-05-02 | 2006-05-01 | METHOD FOR IDENTIFYING A COMPOUND WITH ANTIDEPRESSIVE EFFECT |
CA002606489A CA2606489A1 (en) | 2005-05-02 | 2006-05-01 | Method for identification of compound having antidepressant effect |
AU2006241710A AU2006241710B2 (en) | 2005-05-02 | 2006-05-01 | Method for identification of compound having antidepressant effect |
JP2007514858A JPWO2006118289A1 (ja) | 2005-05-02 | 2006-05-01 | 抗うつ作用を有する化合物の同定方法 |
US11/436,904 US7527937B2 (en) | 2003-11-19 | 2006-05-18 | Assay employing a g-protein coupled receptor that is activated by CCK-8S |
IL186647A IL186647A0 (en) | 2005-05-02 | 2007-10-14 | Method for identification of compound having antidepressant effect |
US12/409,847 US7977069B2 (en) | 2003-11-19 | 2009-03-24 | DNA encoding a CCK-8S G-protein coupled receptor, and vectors, transformants, cell kits, and methods employing such DNA |
US13/113,157 US20110223175A1 (en) | 2003-11-19 | 2011-05-23 | Gene Encoding G-Protein Coupled Receptor And Gene Product Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005134367 | 2005-05-02 | ||
JP2005-134367 | 2005-05-02 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017239 Continuation-In-Part WO2005049833A1 (ja) | 2003-11-19 | 2004-11-19 | G蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017239 Continuation-In-Part WO2005049833A1 (ja) | 2003-11-19 | 2004-11-19 | G蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物 |
US11/436,904 Continuation-In-Part US7527937B2 (en) | 2003-11-19 | 2006-05-18 | Assay employing a g-protein coupled receptor that is activated by CCK-8S |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006118289A1 true WO2006118289A1 (ja) | 2006-11-09 |
Family
ID=37308083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/309118 WO2006118289A1 (ja) | 2003-11-19 | 2006-05-01 | 抗うつ作用を有する化合物の同定方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1884568A4 (ja) |
JP (1) | JPWO2006118289A1 (ja) |
AU (1) | AU2006241710B2 (ja) |
CA (1) | CA2606489A1 (ja) |
IL (1) | IL186647A0 (ja) |
WO (1) | WO2006118289A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008053962A1 (fr) * | 2006-11-02 | 2008-05-08 | Daiichi Sankyo Company, Limited | Procédé d'identification d'un composé ayant un effet anxiolytique |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1084976A (ja) * | 1996-05-16 | 1998-04-07 | Takeda Chem Ind Ltd | 新規ヒトg−蛋白質結合レセプター |
JPH1132766A (ja) * | 1997-05-23 | 1999-02-09 | Otsuka Pharmaceut Co Ltd | ヒトbai遺伝子及びその利用 |
WO2004040000A2 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc | G protein coupled receptors and uses thereof |
WO2005049833A1 (ja) * | 2003-11-19 | 2005-06-02 | Daiichi Pharmaceutical Co., Ltd. | G蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
-
2006
- 2006-05-01 AU AU2006241710A patent/AU2006241710B2/en not_active Ceased
- 2006-05-01 EP EP06745969A patent/EP1884568A4/en not_active Withdrawn
- 2006-05-01 WO PCT/JP2006/309118 patent/WO2006118289A1/ja active Application Filing
- 2006-05-01 CA CA002606489A patent/CA2606489A1/en not_active Abandoned
- 2006-05-01 JP JP2007514858A patent/JPWO2006118289A1/ja not_active Withdrawn
-
2007
- 2007-10-14 IL IL186647A patent/IL186647A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1084976A (ja) * | 1996-05-16 | 1998-04-07 | Takeda Chem Ind Ltd | 新規ヒトg−蛋白質結合レセプター |
JPH1132766A (ja) * | 1997-05-23 | 1999-02-09 | Otsuka Pharmaceut Co Ltd | ヒトbai遺伝子及びその利用 |
WO2004040000A2 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc | G protein coupled receptors and uses thereof |
WO2005049833A1 (ja) * | 2003-11-19 | 2005-06-02 | Daiichi Pharmaceutical Co., Ltd. | G蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物 |
Non-Patent Citations (2)
Title |
---|
See also references of EP1884568A4 * |
SHIRATSUCHI T. ET AL.: "Cloning and characterization of BAI2 and BAI3, novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)", CYTOGENET. CELL GENET., vol. 79, 1997, pages 103 - 108, XP002983770 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008053962A1 (fr) * | 2006-11-02 | 2008-05-08 | Daiichi Sankyo Company, Limited | Procédé d'identification d'un composé ayant un effet anxiolytique |
Also Published As
Publication number | Publication date |
---|---|
EP1884568A1 (en) | 2008-02-06 |
CA2606489A1 (en) | 2006-11-09 |
AU2006241710B2 (en) | 2011-04-14 |
AU2006241710A1 (en) | 2006-11-09 |
EP1884568A4 (en) | 2008-08-27 |
IL186647A0 (en) | 2008-01-20 |
JPWO2006118289A1 (ja) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7666401B2 (en) | Compositions comprising a ligand of Chemerin R | |
US7332291B2 (en) | Methods of identifying modulators of ligand binding to ChemerinR polypeptides | |
JPWO2003082335A1 (ja) | 新規血糖調節薬及びそのスクリーニング方法 | |
US7977069B2 (en) | DNA encoding a CCK-8S G-protein coupled receptor, and vectors, transformants, cell kits, and methods employing such DNA | |
JP4638354B2 (ja) | G蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物 | |
WO2006118289A1 (ja) | 抗うつ作用を有する化合物の同定方法 | |
WO2003055507A1 (fr) | Medicaments contre l'anorexie ou des affections liees au mode de vie et procede de recherche systematique de ces medicaments | |
KR102040893B1 (ko) | Arl6ip1의 유전성 강직성 하반신마비의 치료 용도 | |
US20070213510A1 (en) | Compositions and methods comprising a ligand of ChemerinR | |
US8030453B2 (en) | Methods of making an antibody that binds a chemerin polypeptide | |
WO2008053962A1 (fr) | Procédé d'identification d'un composé ayant un effet anxiolytique | |
ES2359709T3 (es) | Procedimiento de identificación de moduladores de un receptor acoplado a la proteína g. | |
Savdie | Characterization of the cellular and molecular determinants for the internalization of the high affinity neurotensin receptor | |
JPWO2005056597A1 (ja) | 免疫グロブリンFc受容体タンパク質 | |
JP2004065232A (ja) | 新規ポリペプチド、そのdnaおよびそれらの用途 | |
JPWO2004084944A1 (ja) | 新規血糖調節薬及びそのスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 186647 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006241710 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2606489 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007514858 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006241710 Country of ref document: AU Date of ref document: 20060501 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006241710 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006745969 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006745969 Country of ref document: EP |